Allergie Centrum Charité AG Prof. Maurer
Autoinflammation Reference Center Charité
Autoinflammation Network e. V.
COST Action BM1007
Interdisciplinary Mastocytosis Center Charité
International Institute for Dermatological Allergology
SPP Mastzelle
Urticaria Network e. V.

Publikationen - Originalarbeiten:

(Abkürzungen: IF = impact factor, N/A = not applicable, TBD = to be determined, * = authors have contributed equally)

323. Riedl, M.*+, Farkas, H.*, Bernstein, J. A., Bouillet, L., Sheridan, W. P., and Maurer, M.: Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema phrophylaxis trial: the OPUS-2 study. Allergy 2018: in press. IF: TBD (IF 2016: 7.36)
322. Balp, M. M.+, Weller, K., Carboni, V., Chirilov, A., Papavassilis, C., Severin, T., Tian, H., Zuberbier, T., and Maurer, M.: Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatr. Allergy Immunol. 2018: in press. IF: TBD (IF 2016: 3.77)
321. Aygören-Pürsün, E.*+, Bygum, A.*, Grivcheva-Panovska, V., Magerl, M., Graff, J., Steiner, U., Fain, O., Huissoon, A., Kinaciyan, T., Farkas, H., Lleonart, R., Longurst, H., Rae, W., Triggiani, M., Aberer, W., Cancian, M., Zanichelli, A., Smith, W. B., Baeza, M. L., Du-Thanh, A., Gompels, M., Gonzalez-Quevedo, T., Greve, J., Guilarte, M., Katelaris, C., Dobo, S., Cornpropst, M., Clemons, D., Fang, Lei, Collis, P., Sheridan, W., Maurer, M.*, Cicardi, M.: Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New Engl. J. Med. 2018: in press. IF: TBD (IF 2016: 72.40)
320. Aygören-Pürsün, E.+, Magerl, M., Mätzel, A., and Maurer, M.: Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J. Rare Dis. 2018: in press. IF: TBD (IF 2016: 3.47)
319. Maurer, M., Mathias, S. D., Crosby, R. D., Rajput, Y.+, and Zazzali, J. L.: Validity and responsiveness of the urticaria activity and impact measure (U-AIM), a new patient-reported tool. Ann. Allergy Asthma Immunol. 2018: in press. IF: TBD (IF 2016: 3.72)
318. Larenas-Linnemann, D.+, Sainin, S. S., Azamar-Jácome, A. A., and Maurer, M.: Chronic urticaria can be caused by cancer and resolves with its cure. Allergy 2018: in press. IF: TBD (IF 2016: 7.36)
317. Siebenhaar, F.+, Maurer, M., and Weller, K.: Development and validation of the mastocytosis activity score. Allergy 2018: in press. IF: TBD (IF 2016: 7.36)
316. Sussman, G.+, Abuzakouk, M., Bérard, F., Canonica, W., Oude Elberink, H., Giménez-Arnau, A., Grattan, C., Hollis, K., Hunter, S., Knulst, A., Lacour, J. P., Lynde, C., Marsland, A., McBride, D., Maurer, M., Nakonechna, A., Ortiz de Frutos, J., Reynolds, M., Sweeney, C., Tian, H., Weller, K., Wolin, D., and Balp, M. M.: Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy 2018: in press. IF: TBD (IF 2016: 7.36)
315. Altrichter, S., Hawro, T., Liedtke, M., Holtappels, G., Bachert, C., Stahl Skov, P., and Maurer, M.+: In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional. Allergy 2018: in press. IF: TBD (IF 2016: 7.36)
314. Dressler, C.+, Rosumeck, S., Werner, R. N., Magerl., M., Maurer, M., Nast, A., and Zuberbier, T.: Executive summary: methods and evidence report for the evidence – and consensus-based (S3) guideline for the definition, classification, diagnosis and management of urticaria – revision and update 2017. Allergy 2018: in press. IF: TBD (IF 2016: 7.36)
313. Zuberbier, T.+, Aberer, W., Asero, R., Abdul Latiff, A. H., Baker, D., Ballmer-Weber, B., Bernstein, J. A., Bindslev-Jensen, C., Brzoza, Z., Buense Bedrikow, R., Canonica, G. W., Church, M. K., Craig, T., Danilycheva, I. V., Dressler, C., Ensina, L. F., Giménez-Arnau, A., Godse, K., Goncalo, M., Grattan, C., Hebert, J., Hide, M., Kaplan, A., Kapp, A., Katelaris, C. H., Kocatürk, E., Kulthanan, K., Larenas-Linnemann, D., Leslie, T. A., Magerl, M., Mathelier-Fusade, P., Meshkova, R. Y., Metz, M., Nast, A., Nettis, E., Oude-Elberink, H., Rosumeck, S., Saini, S. S., Sánchez-Borges, M., Schmid-Grendelmeier, P., Staubach, P., Sussman, G., Toubi, E., Vena, G. A., Vestergaard, C., Wedi, B., Werner, R. N., Zhao, Z., and Maurer, M.: The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy 2018: in press. IF: TBD (IF 2016: 7.36)
312. Maurer, M.*+, Magerl, M.*, Ansotegui, I., Aygören-Pürsün, E., Betschel, S., Bork, K., Bowen, T., Balle Boysen, H., Farkas, H., Grumach, A. S., Hide, M., Katelaris, C., Lockey, R., Longhurst, H., Lumry, W., Martinez-Saguer, I., Moldovan, D., Nast, A., Pawankar, R., Potter, P., Riedl, M., Ritchie, B., Rosenwasser, L., Sánchez-Borges, M., Zhi, X., Zuraw, B., and Craig, T.: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. Allergy 2018: in press. IF: TBD (IF 2016: 7.36)
311. Schmetzer, O.+, Lakin, E., Topal, F. A., Preusse, P., Freier, D., Church, M. K., and Maurer, M.: IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J. Allergy Clin. Immunol. 2018: in press. IF: TBD (IF 2016: 13.08)
310. Hawro, T., Ohanyan, T., Schoepke, N., Metz, M., Peveling-Oberhag, A., Staubach, P., Maurer, M., and Weller, K.+: The urticaria activity score (UAS) – validity, reliability and responsiveness. J. Allergy Clin. Immunol. Pract. 2018: in press. IF: TBD (IF 2016: 5.31)
309. Kulthanan, K., Tuchinda, P., Chularojanamontri, L. and Maurer, M.+: Food-dependent cold urticaria: a new variant of physical urticaria. J. Allergy Clin. Immunol. Pract. 2018: in press. IF: TBD (IF 2016: 5.31)
308. Maurer, M.*+, Magerl, M.*, Ansotegui, I., Aygören-Pürsün, E., Betschel, S., Bork, K., Bowen, T., Balle Boysen, H., Farkas, H., Grumach, A., Hide, M., Katelaris, C., Lockey, R., Longhurst, H., Lumry, W., Martinez-Saguer, I., Moldovan, D., Nast, A., Pawankar, R., Potter, P., Riedl, M., Ritchie, B., Rosenwasser, L., Sánchez-Borges, M., Zhi, X., Zuraw, B., and Craig, T.: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. WAO Journal 2018: 1-20. IF: N/A
307. Kolkhir, P.*, Altrichter, S.*, Hawro, T., and Maurer, M.+: C-reactive protein is linked to disease activity, impact and response to treatment in patients with chronic spontaneous urticaria. Allergy 2018: 73; 940-948. IF: TBD (IF 2016: 7.36)
306. Bonnekoh, H., Ohanyan, T., Lenze, D., Krause, K., Maurer, M., Zuberbier, T.*, and Siebenhaar, F.*+: Development of tripe palms and soles in a patient with long pre-existing systemic mastocytosis and newly developed non-small cell lung cancer. J. Eur. Acad. Dermatol. Venereol. 2018: 32; e151-e153. IF: TBD (IF 2016: 3.52)
305. Kikuchi, A., Inami, A., Nasir, F. B. M., Mohsen, A., Watanuki, S., Miyake, M., Matsuda, R., Koike, D., Ito, T., Sasakawa, J., Takeda, K., Hiraoka, K., Maurer, M., Yanai, K., Watabe, H., and Tashiro, M.+: Effects of levocetirizine and diphenhydramine on regional glucose metabolic changes and hemodynamic responses in the human prefrontal cortex during cognitive tasks. Hum. Psychopharmacol.-Clin. and Exp. 2018: 33; e2655. IF: TBD (IF 2016: 2.21)
304. Magerl, M., Terhorst, D.+, Metz, M., Zuberbier, T., Altrichter, S., Maurer, M., and Bergmann, K.-C.: Benefit from mepolizumab treatment in a patient with chronic spontaneous urticaria. J. Dtsch. Dermatol. Ges. 2018: 16;477-478. IF: TBD (IF 2016: 2.85)
Magerl, M., Terhorst, D.+, Metz, M., Zuberbier, T., Altrichter, S., Maurer, M., and Bergmann, K.-C.: Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. J. Dtsch. Dermatol. Ges. 2018: 16;476-477
303. Hollis, K.+, Proctor, C., McBride, D., Balp, M. M., McLeod, L., Hunter, S., Tian, H., Khalil, S., and Maurer, M.: Comparison of urticaria activity score over 7 days (UAS7) values obtained from once-daily and twice-daily versions: results from the ASSURE-CSU study. Am. J. Clin. Dermatol. 2018: 19; 267-274. IF: TBD (IF 2016: 2.75)
302. Caballero, T.+, Zanichelli, A., Aberer, W., Maurer, M., Longhurst, H. J., Bouillet, L., and Andresen, I.: Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the icatibant outcome survey, a cohort observational study. Clin. Transl. Allergy 2018: 8; 11. IF: TBD (IF 2016: 3.23)
301. Maurer, M.+, Altrichter, S., Metz, M., Zuberbier, T., Church, M. K., and Bergmann, K. C.: Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. J. Eur. Acad. Dermatol. Venereol. 2018: 32; e112-113. IF: TBD (IF 2016: 3.52)
300. Zänker, M.+, Becher, G., Arbach, O., Maurer, M., Stuhlmüller, B., Schäfer, A., and Strohner, P.: Improved adalimumab dose decision with comprehensive diagnostics data. Clin. Exp. Rheumatol. 2018: 36; 136-139. IF: TBD (IF 2016: 2.63)
299. Bonnekoh, H., Scheffel, J., Maurer, M., and Krause, K.+: The use of skin biomarker profiles to distinguish Schnitzler syndrome from chronic spontaneous urticaria: results of a pilot study. Brit. J. Dermatol. 2018: 18; 561-562. IF: TBD (IF 2016: 4.70)
298. Staubach, P.*, Metz, M.*, Chapman-Rothe, N., Sieder, C., Bräutigam, M., Maurer, M., and Weller, K.+: Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy 2018:73; 576-584. IF: TBD (IF 2016: 7.36)
297. Ertas, R., Ozyurt, K., Atasoy, M., Hawro, T., and Maurer, M.+: The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy 2018:73; 705-712. IF: TBD (IF 2016: 7.36)
296. Ruft, J., Asady, A., Staubach, P., Casale, T., Sussman, G., Zuberbier, T., Maurer, M., Weller, K., and Altrichter, S.+: Development and validation of the cholinergic urticaria quality of life questionnaire: CholU-QoL. Clin. Exp. Allergy 2018: 48; 1-12. IF: TBD (IF 2016: 5.26)
295. Maurer, M.+, Kaplan, A., Rosén, K., Holden, M., Iqbal, A., Trzaskoma, B. L., Yang, M., and Casale, T. B.: The XTEND-CIU study: long term use of omalizumab in chronic idiopathic urticaria. J. Allergy Clin. Immunol. 2018:141; 1138-1139. IF: TBD (IF 2016: 13.08)
294. Kulthanan, K., Chaweekulrat, P., Komoltri, C., Hunnangkul, S., Tuchinda, P.+, Chularojanamontri, L., and Maurer, M.: Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. J. Allergy Clin. Immunol. Pract. 2018:6; 586-599. IF: TBD (IF 2016: 5.31)
293. Terhorst, D., Koti, I., Krause, K., Metz, M., and Maurer, M.+: In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angioedema. Clin. Exp. Dermatol. 2018: 43; 131-136. IF: TBD (IF 2016: 1.58)
292. Ohanyan, T., Schoepke, N., Eirefelt, S., Hoey, G., Koopmann, W., Hawro, T., Maurer, M., and Metz, M.+: The role of substance P and its receptor NK1R in chronic prurigo: results from a randomized, controlled trial with topical aprepitant. Acta Derm. Venereol. 2018: 98; 26-31. IF: TBD (IF 2016: 3.65)
291. Hawro, T., Ohanyan, T., Schoepke, N., Metz, M., Peveling-Oberhag, A., Staubach, P., Maurer, M., and Weller, K.+: Comparison and interpretability of the available urticaria activity scores. Allergy 2018: 73; 251-255. IF: TBD (IF 2016: 7.36)
290. Suender, C. A., Leist, M., Abrink, M., Valentin, P., Geldmacher, A., Steinhoff, M., Metz, M., and Maurer, M.+: Mast cells are critical for the limitation of thrombin-induced skin inflammation. Exp. Dermatol. 2018: 27; 50-57. IF: TBD (IF 2016: 2.67)
289. Gianni, P., Loules, G., Zamanakou, M., Kompoti, M., Csuka, D., Psarros, F., Magerl, M., Moldovan, D., Maurer, M., Speletas, M. G., Farkas, H., and Germenis, A. E.+: Genetic determinants of C1 inhibitor deficiency angioedema age of onset. Int. Arch. Allergy Immunol. 2017: 174; 200-204. IF: TBD (IF 2016: 2.72)
288. Ohanyan, T., Schoepke, N., Bolukbasi, B., Metz, M., Hawro, T., Zuberbier, T., Peveling-Oberhag, A., Staubach, P., Maurer, M., and Weller, K.+: Responsiveness and minimal important difference of the urticaria control test (UCT). J. Allergy Clin. Immunol. 2017: 140; 1710-1713. IF: TBD (IF 2016: 13.08)
287. Ertas, R., Ozyurt, K., Ozlu, E., Ulas, Y., Avci, A., Atasoy, M., Hawro, T., and Maurer, M.+: Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. J. Allergy Clin. Immunol. 2017: 140; 1749-1751. IF: TBD (IF 2016: 13.08)
286. Irani, C., Hallit, S.+, Weller, K., Maurer, M., El Haber, C., and Salameh, P.: Chronic urticaria in most patients is poorly controlled: Results of the development, validation, and real life application of the Arabic urticaria control test. Saudi Med. J. 2017: 38; 179-185. IF: TBD (IF 2016: 0.71)
285. Maurer, M.+, Abuzakouk, M., Bérard, F., Canonica, W., Oude Elberink, H., Giménez-Arnau, A., Grattan, C., Hollis, K., Knulst, A., Lacour, J. P., Lynde, C., Marsland, A., McBride, D., Nakonechna, A., Ortiz de Frutos, J., Proctor, G., Sweeney, C., Tian, H., Weller, K., Wolin, D., and Balp, M. M.: The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017: 72; 2005-2016. IF: TBD (IF 2016: 7.36)
284. Stull, D.+, McBride, D., Tian, H., Giménez-Arnau, A., Maurer, M., Marsland, A., Balp, M. M., Khalil, S., and Grattan, C.: Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Brit. J. Dermatol. 2017: 177; 1093-1101. IF: TBD (IF 2016: 4.70)
283. Metz, M.+, Schütz, A., Weller, K., Gorczyza, M., Zimmer, S., Staubach, P., Merk, H. F., and Maurer, M.: Omalizumab is effective in cold urticaria – results of a randomized, placebo controlled trial. J. Allergy Clin. Immunol. 2017: 140; 864-867. IF: TBD (IF 2016: 13.08)
282. Maurer, M.+, Schütz, A., Weller, K., Schoepke, N., Peveling-Oberhag, A., Staubach, P., Müller, S., Jakob, T., and Metz, M.: Omalizumab is effective in symptomatic dermographism – results of a randomized, placebo controlled trial. J. Allergy Clin. Immunol. 2017: 140; 870-873. IF: TBD (IF 2016: 13.08)
281. Finlay, A. Y.+, Kaplan, A. P., Beck, L. A., Antonova, E. N., Balp, M. M., Zazzali, J., Khalil, S., and Maurer, M.: Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J. Eur. Acad. Dermatol. Venereol. 2017: 31; 1715-1721. IF: TBD (IF 2016: 3.52)
280. Asady, A., Ruft, J., Ellrich, A., Hawro, T., Maurer, M.+, and Altrichter, S.: Cholinergic urticaria patients of different age groups have distinct features. Clin. Exp. Allergy 2017: 47; 1609-1614. IF: TBD (IF 2016: 5.26)
279. Aberer, W.+, Maurer, M., Bouillet, L., Zanichelli, A., Caballero, T., Longhurst, H. J., Perrin, A., and Andresen, I.: Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the icatibant outcome survey. Allerg. Asthma Clin. Immunol. 2017: 13; 31. IF: TBD (IF 2016: 2.86)
278. Caballero, T.+, Aberer, W., Longhurst, H. J., Maurer, M., Zanichelli, A., Perrin, A., Bouillet, L., and Andresen, I.: The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. J. Eur. Acad. Dermatol. Venereol. 2017:31; 1214-1222. IF: TBD (IF 2016: 3.52)
277. Maurer, M.+, Sofen, H., Ortiz, B., Kianifard, F., Gabriel, S., and Bernstein, J. A.: Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J. Eur. Acad. Dermatol. Venereol. 2017: 31; 1056-1063. IF: TBD (IF 2016: 3.52)
276. Tabeling, C., Herbert, J., Hocke, A. C., Lamb, D., Wollin, L., Erb, K., Boiarina, E., Movassagh, H., Scheffel, J., Doehn, J. M., Hippenstiel, S., Maurer, M., Gounni, A., S., Kuebler, W. M., Suttorp, N., and Witzenrath, M.: Spleen tyrosine kinase inhibition blocks airway constriction and protects from Th2-induced airway inflammation and remodeling. Allergy 2017: 72; 1061-1072. IF: TBD (IF 2016: 7.36)
275. Meyer, N., Woidacki, K., Maurer, M., and Zenclussen, A. C.: Safeguarding of fetal growth by mast cells and natural killer cells: deficiency of one is counterbalanced by the other. Front. Immunol. 2017: 8; 711. IF: TBD (IF 2016: 5.69)
274. Maurer, M.*, Staubach, P.*, Raap, U.*, Richter-Huhn, G.*, Bauer, A., Ruëff, F., Jakob, T., Yazdi, A. S., Mahler, V., Wagner, N., Lippert, U., Hillen, U., Schwinn, A., Pawlak, M., Behnke, N., Chaouche, K., and Chapman-Rothe, N.: H1-antihistamine-refractory chronic spontaneous urticaria: It’s worse than we thought – first results of the multicenter real-life AWARE study. Clin. Exp. Allergy 2017: 47; 684-692. IF: TBD (IF 2016: 5.26)
273. Zanichelli, A., Maurer, M., Aberer, W., Caballero, T., Longhurst, H., Bouillet, L., Fabien, V., and Andresen, I.: Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice. Allergy 2017: 72; 994-998. IF: TBD (IF 2016: 7.36)
272. Garbani, M., Xia, W., Rhyner, C., Prati, M., Scheynius, A., Malissen, B., Engqvist, H., Maurer, M., Crameri, R., and Terhorst, D.: Allergen-loaded strontium-doped hydroxyapatite spheres improve allergen-specific immunotherapy in mice. Allergy 2017: 72; 570-578. IF: TBD (IF 2016: 7.36)
271. Krause, K., Tsianakas, A., Wagner, N., Fischer, J., Weller, K., Metz, M., Church, M. K., and Maurer, M.: Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. J. Allergy Clin. Immunol. 2017: 139; 1311-1320. IF: TBD (IF 2016: 13.08)
270. Cherrez, A., Maurer, M., Weller, K., Calderon, J. C., Simancas-Racines, D., and Cherrez-Ojeda, I.: Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador. WAO Journal 2017: 10; 21. IF: N/A
269. Metz, M., Staubach, P., Bauer, A., Brehler, R., Gericke, J., Kangas, M., Ashton-Chess, J., Jarvis, P., Georgiou, P., Canvin, J., Hillenbrand, R., Erpenbeck, V. J., and Maurer, M.: Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FceRI-positive cells in the skin. Theranostics 2017: 7;1266-1276. IF: TBD (IF 2016: 8.71)
268. Hawro, M., Maurer, M., Weller, K., Maleszka, R., Zalewska-Janowska, A., Kaszuba, A., Gerlicz-Kowalczuk, Z., and Hawro, T.: Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. J. Am. Acad. Dermatol. 2017: 76; 648-654. IF: TBD (IF 2016: 7.00)
267. Leist, M., Sünder, C. A., Drube, S., Zimmermann, C., Geldmacher, A., Metz, M., Dudeck, A., and Maurer, M.: Membrane-bound stem cell factor is the major but not only driver of fibroblast-induced murine skin mast cell differentiation. Exp. Dermatol. 2017: 26; 255-262. IF: TBD (IF 2016: 2.67)
266. Gericke, J.*, Metz, M.*, Ohanyan, T., Weller, K., Altrichter, S., Stahl Skov, P., Falkencrone, S., Brand, J., Kromminga, A., Hawro, T., Church, M. K., and Maurer, M.: Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J. Allergy Clin. Immunol. 2017: 139; 1059-1061. IF: TBD (IF 2016: 13.08)
265. Weller, K., Maurer, M., Fridman, M., Supina, D., Schranz, J., and Magerl, M.: Health-related quality of life in hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy Asthma Proc. 2017: 38; 143-151. IF: TBD (IF 2016: 2.61)
264. Gorczyza, M., Schoepke, N., Krause, K., Hawro, T., and Maurer, M.: Patients with chronic cold urticaria may benefit from doxycycline therapy. Brit. J. Dermatol. 2017: 176; 259-261. IF: TBD (IF 2016: 4.70)
263. Longhurst, H. J., Zanichelli, A., Caballero, T., Bouillet, L., Aberer, W., Maurer, M., Fain, O., Fabien, V., and Andresen, I.: Comparing acquired angioedema with hereditary angioedema (type I/II): findings from the icatibant outcome survey. Clin. Exp. Immunol. 2017: 188; 148-153. IF: TBD (IF 2016: 3.41)
262. Weller, K., Magerl, M., Peveling-Oberhag, A., Martus, P., Staubach, P., and Maurer, M.: The angioedema quality of life questionnaire (AE-QoL) – assessment of sensitivity to change and minimal clinically important difference. Allergy 2016: 71; 1203-1209. IF: 7.36
261. Staubach, P., Metz, M., Chapman-Rothe, N., Sieder, C., Bräutigam, M., Canvin, J., and Maurer, M.: Effect of omalizumab on angioedema in H1-antihistamine resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 2016: 71; 1135-1144. IF: 7.36
260. Altrichter, S., Koch, K., Church, M. K., and Maurer, M.: Atopic predisposition in cholinergic urticaria patients and its implications. J. Eur. Acad. Dermatol. Venereol. 2016: 30; 2060-2065. IF: 3.52
259. Hawro, T., Lehmann, S., Altrichter, S., Fluhr, J. W., Zuberbier, T., Church, M. K., Maurer, M., and Metz, M.: Skin provocation tests may help to diagnose atopic dermatitis. Allergy 2016: 71; 1745-1752. IF: 7.36
258. Maurer, M., Metz, M., Bindslev-Jensen, C., Bousquet, J., Canonica, G. W., Church, M. K., Godse, K. V., Grattan, C. E., Hide, M., Kocatürk, E., Magerl, M., Makris, M., Meshkova, R., Saini, S. S., Sussman, G., Toubi, E., Zhao, Z., Zuberbier, T., and Gimenez-Arnau, A.: Definition, aims, and implementation of GA²LEN urticaria centers of reference and excellence. Allergy 2016: 71; 1210-1218. IF: 7.36
257. Caballero, T., Maurer, M., Longhurst, H. J., Aberer, W., Bouillet, L., and Fabien, V.: Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J. Invest. Allerg. Clin. Immunol. 2016: 26; 383-386. IF: 3.09
256. Azar, R. P., Thomas, A. H., Maurer, M., and Lindner, G.: Asymmetry of the receding hairline in men with early androgenetic alopecia. J. Cutan. Med. Surg. 2016: 20; 546-549. IF: 0.89
255. Harris, J. M., Cabanski, C. R., Scheerens, H., Samineni, D., Bradley, M. S., Cochran, C., Staubach, P., Metz, M., Sussman, G., and Maurer, M.: A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. J. Allergy Clin. Immunol. 2016: 138; 1730-1732. IF: 13.08
254. Gimenez-Rivera, V. A., Siebenhaar, F., Zimmermann, C., Siiskonen, H., Metz, M., and Maurer, M.: Mast cells limit the exacerbation of chronic allergic contact dermatitis in response to repeated allergen exposure. J. Immunol. 2016: 197; 4240-4246. IF: 4.85
253. Riedl, M. A., Lumry, W. R., Li, H., Banerji, A., Bernstein, J. A., Bas, M., Björkander, J., Magerl, M., Maurer, M., Rockich, K., Chen, H., and Schranz, J.: Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy Asthma Proc. 2016: 37; 489-500. IF: 2.61
252. Krull, C., Schoepke, N., Ohanyan, T., Brachaczek, M., Maurer, M., Lange-Asschenfeldt, B.*, and Metz, M.*: Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients. J. Eur. Acad. Dermatol. Venereol. 2016: 30; 1357-1361. IF: 3.52
251. Netchiporouk, E., Moreau, L., Rahme, E., Maurer, M., Lejtenyi, D., and Ben-Shoshan, M.: Positive CD63 basophil activation tests are common in children with chronic spontaneous urticaria and linked to high disease activity. Int. Arch. Allergy Immunol. 2016: 171; 81-88 IF: 2.72
250. Koch, K., Weller, K., Werner, A., Maurer, M., and Altrichter, S.: Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria patients. J. Allergy Clin. Immunol. 2016: 138; 1483-1485. IF: 13.08
249. Kessel, A., Graif, Y., Vadasz, Z., Schichter-Konfino, V., Almog, M., Cohen, S., Teplitski, V., Stein, N., Baiardini, I. Maurer, M., and Toubi, E.: Adaption and validation of the Israeli version of the chronic urticaria quality of life questionnaire (CU-Q2oL). IMAJ 2016: 18; 461-465. IF: 1.03
248. Ständer, S., Metz, M., Ramos, M. H., Maurer, M., Schoepke, N., Tsianakas, A., Zeidler, C., and Luger, T. A.: Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability. Acta Derm. Venereol. 2016: 96; 792-796. IF: 3.65
247. Azar, R. P., Thomas, A. H., Maurer, M., and Lindner, G.: Alterations in hair follicle morphology and hair shaft production after follicular unit transplantation. Am. J. Dermatopathol. 2016: 38; 732-738. IF: 1.09
246. Aygören-Pürsün, E.*, Magerl, M.*, Graff, J., Martinez-Saguer, I., Kreuz, W., Longhurst, H., Nasr, I., Bas, M., Straßen, U., Fang, L., Cornprobst M.; Dobo, S., Collis, P., Sheridan, W. P., and Maurer, M.: Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat. J. Allergy Clin. Immunol. 2016: 138; 934-936. IF: 13.08
245. Zazzali, J. L., Kaplan, A., Maurer, M., Raimundo, K., Trzaskoma, B., Solari, P. G., Antonova, E., Mendelson, M., and Rosén, K.: Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Ann. Allergy Asthma Immunol. 2016: 117; 370-377. IF: 3.72

Zazzali, J. L., Kaplan, A., Maurer, M., Raimundo, K., Trzaskoma, B., Antonova, E. N., and Rosén, K. E.: Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria. Ann. Allergy Asthma Immunol. 2017: 118; 524-526
244. Zanichelli, A., Longhurst, H. J., Maurer, M., Bouillet, L., Aberer, W., Fabien, V., Andresen, I., and Caballero, T.: Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Ann. Allergy Asthma Immunol. 2016: 117; 394-398. IF: 3.72
243. Siebenhaar, F., Melde, A., Magerl, M., Zuberbier, T., Church, M. K., and Maurer, M.: Histamine intolerance in patients with chronic spontaneous urticaria. J. Eur. Acad. Dermatol. Venereol. 2016: 30; 1774-1777. IF: 3.52
242. Zhao, Z.*, Ji, C.*, Yu, W.*, Meng, L., Hawro, T., Wei, J. F., and Maurer, M.: Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J. Allergy Clin. Immunol. 2016: 137; 1742-1750. IF: 13.08
241. Magerl, M., Altrichter, S., Borzova, E., Giménez-Arnau, A., Grattan, C. E. H., Lawlor, F., Mathelier-Fusade, P., Meshkova, R. Y., Zuberbier, T., Metz, M., and Maurer, M.: The definition, diagnostic testing and management of chronic inducible urticarias –The EAACI/GA²LEN/EDF/UNEV 2016 consensus panel recommendations 2016 update and revision. Allergy 2016: 71; 780-802. IF: 7.36
240. Siebenhaar, F., von Tschirnhaus, E., Hartmann, K., Rabenhorst, A., Staubach, P., Peveling-Oberhag, A., Wagner, N., Martus, P., Carter, M. C., Metcalfe, D. D., Church, M. K., Maurer, M., and Weller, K.: Development and Validation of the Mastocytosis Quality of Life questionnaire: MC-QoL. Allergy 2016: 71; 869-877. IF: 7.36
239. Maurer, M., Staubach, P., Raap, U., Richter-Huhn, G., Baier-Ebert, M., and Chapman-Rothe, N.: ATTENTUS, a German survey of chronic urticaria patients highlightening the burden of disease unmet needs and real-life clinical practice. Brit. J. Dermatol. 2016: 174; 892-894. IF: 4.70
238. Weller, K., Krüger, R., Maurer, M., and Magerl, M.: Subcutaneous self-injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angioedema. Clin. Exp. Dermatol. 2016: in press. IF: 1.58
237. Altrichter, S., Hawro, T., Hänel, K., Czaja, K., Lüscher, B., Maurer, M., Church, M. K., and Baron, J. M.: Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels. J. Eur. Acad. Dermatol. Venereol. 2016: 30; 454-455. IF: 3.52
236. Vadasz, Z., Kessel, A., Hershko, A. Y., Maurer, M., and Toubi, E.: Seasonal exacerbation of asthma is frequently associated with recurrent episodes of acute urticaria. Int. Arch. Allergy Immunol. 2016: 169; 263-266. IF: 2.72
235. Inami, A., Matsuda, R., Grobosch, T., Komamura, H., Takeda, K., Yamada, Y., Miyake, M., Hiraoka, K., Maurer, M., Yanai, K., and Tashiro, M.: A simulated car-driving study on the effects of acute administration of levocetirizine, fexofenadine, and diphenhydramine in healthy Japanese volunteers. Hum. Psychopharmacol Clin. Exp. 2016: 31; 167-177. IF: 2.21
234. Longhurst, H. J., Aberer, W., Bouillet, L., Caballero, T., Maurer, M., Fabien, V., Zanichelli, A.: The icatibant outcome survey: treatment of laryngeal angioedema attacks. Eur. J. Emerg. Med. 2016: 23; 224-227. IF: 2.02
233. Kulthanan, K., Chularojanamontri, L., Tuchinda, P., Rujitharanawong, C., Maurer, M., and Weller, K.: Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). Health Qual. Life Outcomes 2016: 14; 61. IF: 2.14
232. Abajian, M., Curto-Barredo, L., Krause, K., Santamaria, E., Izquierdo, I., Church, M. K., Maurer, M., and Giménez-Arnau, A.: Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria. Acta Derm. Venereol. 2016: 96; 56-59. IF: 3.65
231. Potter, P., Mitha, E., Barkai, L., Gyorgyl, M., Santamaria, E., Izquierdo, I., and Maurer, M.: Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. Pediatr. Allergy Immunol. 2016: 27; 55-61. IF: 3.77
230. Hartmann, K. Escribano, L., Grattan, C., Brockow, K., Carter, M. C., Alvarez-Twose, I., Matito, A., Broesby-Olsen, S., Siebenhaar, F., Lange, M., Niedoszytko, M., Castells, M., Oude Elberink, J. N. G., Bonadonna, P., Zanotti, R., Hornick, J. L., Torrelo, A., Grabbe, J., Rabenhorst, A., Nedoszytko, B., Butterfield, J. H., Gotlib, J., Reiter, A., Radia, D., Hermine, O., Sotlar, K., George, T. I., Kristensen, T. K., Kluin-Nelemans, H. C., Yavuz, S., Hägglung, H., Sperr, W. R., Schwartz, L. B., Triggiani, M., Maurer, M., Nilsson, G., Horny, H. P., Arock, M., Orfao, A., Metcalfe, D. D., Akin, C., and Valent, P.: Cutaneous manifestations in mastocytosis: consensus report of the European Competence Network on Mastocytosis (ECNM), AAAAI and EAACI. J. Allergy Clin. Immunol. 2016: 137; 35-45. IF: 13.08
229. Metz, M., Weller, K., Neumeister, C., Izquierdo, I., Bödeker, R. H., Schwantes, U., and Maurer, M.: Rupatadine in established treatment schemes improves chronic spontaneous urticaria symptoms and patients quality of life: a prospective, non-interventional trial. Dermatol. Ther. 2015: 5; 217-230. IF: 1.26
228. Gericke, J., Ohanyan, T., Church, M. K., Maurer, M., and Metz, M.: Omalizumab may not inhibit mast cell and basophil activation in vitro. J. Eur. Acad. Dermatol. Venereol. 2015: 29; 1832-1836. IF: 2.82
227. Hawro, T., Bogucki, A., Krupinska-Kun, M., Maurer, M.*, and Wozniacka, A.*: Serum neuron specific enolase – a novel indicator for neuropsychiatric systemic lupus erythematosus? Lupus 2015: 24; 1492-1497. IF: 2.11
226. Garcia-Diez, I., Curto-Barredo, L., Weller, K., Pujol, R. M., Maurer, M., and Giménez-Arnau, A. M.: Cross-cultural adaption of the urticaria control test from German to Castilian Spanish. Actas Dermosifiliogr. 2015: 106; 746-752. IF: N/A
225. Speletas, M., Szilagyi, A., Csuka, D., Koutsostathis, N., Psarros, F., Moldovan, D., Magerl, M., Kompoti, M., Varga, L., Maurer, M., Farkas, H., and Germenis, A. E.: F12-46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema. Allergy 2015: 70; 1661-1664. IF: 6.33
224. Altrichter, S., Wosny, K., and Maurer, M.: Successful treatment of cholinergic urticaria with methantheliniumbromide. J. Dermatol. 2015: 42; 422-4249. IF: 1.57
223. Kay, A. B., Clark, P., Maurer, M., and Ying, S.: Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (“idiopathic”) urticaria. Brit. J. Dermatol. 2015: 172; 1294-1302. IF: 4.31
222. Schubert, N., Dudeck, J., Liu, P., Karutz, A., Speier, S., Maurer, M., Tuckermann, J., and Dudeck, A.: Mast cell promotion of T cell-driven antigen-induced arthritis despite being dispensable for antibody-induced arthritis in which T cells are bypassed. Arthritis Rheumatol. 2015: 67; 903-913. IF: 6.00
221. Craig, T., Aygören Pürsün, E. A., Bork, K., Bowen, T., Boysen, H., Farkas, H., Grumach, A. S., Katelaris, C. H., Lockey, R., Longhurst, H., Lumry, W., Magerl, M., Martinez-Saguer, I., Ritchie, B., Nast, A., Pawankar, R., Zuraw, B. L., and Maurer, M.: WAO Guideline for the management of hereditary angioedema Arerugi 2015: 64; 1215-1241. IF: N/A
220. Woidacki, K.*, Meyer, N.*, Schumacher, A., Goldschmidt, A., Maurer, M., and Zenclussen, A. C.: Transfer of regulatory T cells into abortion-prone mice promotes the expansion of uterine mast cells and normalizes early pregnancy angiogenesis. Sci. Rep. 2015: 5-13938 IF: 5.22
219. Weller, K., Maurer, M., Grattan, C., Nakonechna, A., Abuzakouk, M., Bérard, F., Sussman, G., Giménez-Arnau, A. M., Ortiz de Frutos, J., Knulst, A., Canonica, G. W., Hollis, K., McBride, D., and Balp, M. M.: ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clin. Transl. Allergy 2015: 5;29. IF N/A
218. Serra-Pages, M.*, Torres, R.*, Plaza, J., Herrerias, A., Costa-Farré, C., Jiménez, M., Maurer, M., Picado, C., and de Mora, F.: Activation of the prostaglandin E2 receptor EP2 prevents house dust mite-induced airway hyperresponsiveness and inflammation by restraining mast cells activity. Clin. Exp. Allergy 2015: 45; 1590-1600. IF: 5.58
217. Netchiporouk, E., Nguyen, C. H., Thuraisingham, T., Jafarian, F., Maurer, M., and Ben-Shoshan, M.: Management of pediatric chronic spontaneous and physical urticaria patients with Omalizumab: case series. Pediatr. Allergy Immunol. 2015:26; 585-588. IF: 3.94
216. Bonner, N., Abetz-Webb, L., Renault, L., Caballero, T., Longhurst, H., Maurer, M., Christiansen, S., and Zuraw, B.: Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies. Health Qual. Life Outcomes 2015: 13; 92. IF: 2.21
215. Bousquet, J., Schunemann, H. J., Fonseca, J., Samolinski, B., Bachert, C., Canonica, G. W., Casale, T., Cruz, A. A., Demoly, P., Hellings, P., Valiulis, A., Wickman, M., Zuberbier, T., Bosnic-Anticevitch, S., Bedbrook, A., Bergmann, K. C., Caimmi, D., Dahl, R., Fokkens, W. J., Grisle, I., Lodrup Carlsen, K., Mullol, J., Muraro, A., Palkonen, S., Papadopoulos, N., Passalacqua, G., Ryan, D., Valovirta, E., Yorgancioglu, A., Aberer, W., Agache, I., Adachi, M., Akdis, C. A., Akdis, M., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Arnavielle, S., Arshad, H., Baiardini, I., Baigenzhin, A. K., Barbara, C., Bateman, E. D., Beghé, B., Bel, E. H., Ben Kheder, A., Bennoor, K. S., Benson, M., Bewick, M., Bieber, T., Bindslev-Jensen, C., Bjermer, L., Blain, H., Boner, A. L., Boulet, L. P., Bonini, M., Bonini, S., Bosse, I., Bourret, R., Bousquet, P. J., Braido, F., Briggs, A. H., Brightling, C. E., Brozek, J., Buhl, R., Burney, P. G., Bush, A., Caballero-Fonseca, F., Calderon, M. A., Camargos, P., Camuzat, T., Carlsen, K. H., Carr, W., Cepeda Sarabia, A. M., Chavannes, N. H., Chatzi, L., Chen, Y. Z., Chiron, R., Chkhartishvili, E., Chuchalin, A. G., Ciprandi, G., Cirule, I., Correia de Sousa, J., Cox, L., Crooks, G., Costa, D. J., Custovic, A., Dahlen, S. E., Darsow, U., De Carlo, G., De Blay, F., Dedeu, T., Deleanu, D., Denburg, J. A., Devillier, P., Didier, A., Dinh-Xuan, A. T., Dokic, D., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Dykewicz, M. S., El-Gamal, Y., Emuzyte, R., Fink Wagner, A., Fletcher, M., Fiocchi, A., Forastiere, F., Gamkrelidze, A., Gemicioglu, B., Gereda, J. E., González Diaz, S., Gotua, M., Grouse, L., Guzmán, M. A., Haahtela, T., Hellquist-Dahl, B., Heinrich, J., Horak, F., Hourihane, J., Howarth, P., Humbert, M., Hyland, M. E., Ivancevich, J. C., Jares, E. J., Johnston, S. L., Joos, G., Jonquet, O., Jung, K. S., Just, J., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Keil, T., Keith, P. K., Khaltaev, N., Klimek, L., N'Goran, B. K., Kolek, V., Koppelman, G. H., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Lambrecht, B., Lau, S., Larenas-Linnemann, D., Laune, D., Le, L., Lieberman, P., Lipworth, B., Li, J., Louis, R., Magard, Y., Magnan, A., Mahboub, B., Majer, I., Makela, M. J., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maurer, M., Mavale-Manuel, S., Melén, E., Melo-Gomes, E., Meltzer, E. O., Merk, H., Miculinic, N., Mihaltan, F., Milenkovic, B., Mohammad, Y., Molimard, M., Momas, I., Montilla-Santana, A., Morais-Almeida, M., Mösges, R., Namazova-Baranova, L., Naclerio, R., Neou, A., Neffen, H., Nekam, K., Niggemann, B., Nyembue, T. D., O'Hehir, R. E., Ohta, K., Okamoto, Y., Okubo, K., Ouedraogo, S., Paggiaro, P., Pali-Schöll, I., Palmer, S., Panzner, P., Papi, A., Park, H. S., Pavord, I., Pawankar, R., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Postma, D., Potter, P., Price, D., Rabe, K. F., Raciborski, F., Radier, Pontal, F., Repka-Ramirez, S., Robalo-Cordeiro, C., Rolland, C., Rosado-Pinto, J., Reitamo, S., Rodenas, F., Roman Rodriguez, M., Romano, A., Rosario, N., Rosenwasser, L., Rottem, M., Sánchez-Borges, M., Scadding, G. K., Serrano, E., Schmid-Grendelmeier, P., Sheikh, A., Simons, F., Sisul, J. C., Skrindo, I., Smit, H. A., Solé, D., Sooronbaev, T., Spranger, O., Stelmach, R., Strandberg, T., Sunyer, J., Thijs, C., Todo-Bom, A., Triggiani, M., Valenta, R., Valero, A. L., van Hage, M., Vandenplas, O., Vezzani, G., Vichyanond, P., Viegi, G., Wagenmann, M., Walker, S., Wang, D. Y., Wahn, U., Williams, D.M., Wright, J., Yawn, B. P., Yiallouros, P. K., Yusuf, O. M., Zar, H. J., Zernotti, M. E., Zhang, L., Zhong, N., Zidarn, M., and Mercier, J.: MACVIA-ARIA sentinel network for allergic rhinitis (MASK-rhinitis): The new generation guideline implementation. Allergy 2015: 11; 1372-1392. IF: 6.33
214. Longhurst, H., Aberer, W., Bouillet, L., Caballero, T., Fabien, V., Zanichelli, A., and Maurer, M.: Analysis of characteristics associated with reinjection of icatibant: results from the icatibant outcome survey. Allergy Asthma Proc. 2015: 36; 399-406. IF: 2.70
213. Maurer, M., Church, M. K., Metz, M., Starkhammar, M., Hamsten, C., and van Hage, M.: Galactose-a-1,3-galactose allergy is not a hitherto unrecognized cause of chronic spontaneous urticaria. Int. Arch. Allergy Immunol. 2015: 167; 250-252. IF:
212. Hernández Fernández de Rojas, D., Ibánez, E., Longhurst, H., Maurer, M., Fabien, V., Aberer, W., Laurence Bouillet, L., Zanichelli, A., and Caballero, T.: Treatment of HAE attacks in the icatibant outcome survey: an analysis of icatibant self-administration versus administration by health care professionals. Int. Arch. Allergy Immunol. 2015: 167; 21-28. IF: 2.67
211. Casale, T. B., Bernstein, J. A., Maurer, M., Saini, S. S., Trzaskoma, B., Chen, H., Grattan, C., Gimenèz-Arnau, A., Kaplan, A. P., and Rosén, K.: Similar efficacy with Omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J. Allergy Clin. Immunol. Pract. 2015: 3; 743-750. IF: 5.42
210. Schoepke, N., Mlynek, A., Weller, K., Church, M. K., and Maurer, M.: Symptomatic dermographism: an inadequately described disease. J. Eur. Acad. Dermatol. Venereol. 2015: 29; 708-712. IF: 2.82
209. Termeer, C., Staubach, P., Kurzen, H., Strömer, K., Ostendorf, R., and Maurer, M.: Chronic spontaneous urticaria – a management pathway for patients with chronic spontaneous urticaria. J. Dtsch. Dermatol. Ges. 2015: 13; 419-428. IF: 2.51
208. Hawro, T., Bogucki, A., Krupinska-Kun, M., Maurer, M.*, and Wozniacka, A.*: Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-b2GPI antibodies in patients with systemic lupus erythematosus. PLoS ONE 2015: 10; e0119911. IF: 3.05
207. Ngouateu, O. B., Weller, K., Bröhl, K., Kamtchouing, P., Same-Ekobo, A., Dondji, B.*, Maurer, M.*, and Stebut, E.*: Impaired T cell-dependent protection against Leishmania major infection in HIV-positive patients is associated with worsened disease outcome. Exp. Dermatol. 2015: 24; 302-304. IF: 2.67
206. Hawro, T., Zalewska, A., Hawro, M., Kaszuba, A., Królikowska, M., and Maurer, M.: Impact of psoriasis severity on family income and quality of life. J. Eur. Acad. Dermatol. Venereol. 2015: 29; 438-443. IF: 2.82
205. Speletas, M., Szilagyi, A., Psarros, F., Moldovan, D., Magerl, M., Kompoti, M., Gramoustianou, E., Bors, A., Mihaly, E., Tordai, A., Avramouli, A., Varga, L., Maurer, M., Farkas, H., and Germenis, A. E.: Hereditary angioedema: Molecular and clinical differences among European populations. J. Allergy Clin. Immunol. 2015: 135; 570-573. IF: 12.48
204. Saini, S. S., Bindslev-Jensen, C., Maurer, M., Grob, J.-J., Baskan, E. B., Bradley, M. S., Canvin, J., Rahmaoui, A., Georgiou, P., Alpan, O., Spector, S., and Rosén, K.: Efficacy and safety of Omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1-antihistamines: A randomized, placebo-controlled study. J. Invest. Dermatol. 2015:135; 67-75. IF: 6.91
203. Lengweiler, S.*, Kreim, S.*, Barman-Aksozen, J., Maurer, M. and Minder, E.: Evaluation of the immunogenicity of the α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle 4-D-Phe 7] - α-MSH, scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti- α -MSH antibodies. Skin Pharmacol. Physiol. 2015: 28; 103-113. IF: 2.48
202. Schmetzer, O., Valentin, P., Smorodchenko, A., Domenis, R., Gri, G., Siebenhaar, F., Metz, M., and Maurer, M.: A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs). J. Immunol. Methods 2014: 413; 62-68. IF: 2014: 1.82
201. Hawro, T., Saluja, R., Weller, K., Altrichter, S., Metz, M.*, and Maurer, M.*: Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy 2014: 69; 113-117. IF: 6.03
200. Kay, A. B., Ying, S., Ardelean, E., Mlynek, A., Kita, H., Clark, P., and Maurer, M.: Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low level persistence in uninvolved skin. Brit. J. Dermatol. 2014: 171; 505-511. IF: 4.27
199. Valent, P., Escribano, L., Broesby-Olsen, S., Hartmann, K., Grattan, C., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, J. N., Kristensen, T., Butterfield, J. H., Triggiani, M., Alvarez-Twose, I., Reiter, A., Sperr, W. R., Sotlar, K., Yavuz, S., Kluin-Nelemans, H. C., Hermine, O., Radia, D., Gotlib, J., Orfao, A., Siebenhaar, F., Schwartz, L. B., Castells, M., Maurer, M., Horny, H.-P., Akin, C., Metcalfe, D. D., and Arock, M.: Proposed diagnostic algorithm for patients with suspected mastocytosis: A proposal of the European Competence Network on Mastocytosis (ECNM). Allergy 2014: 69; 1267-1274. IF: 6.03
198. Metz, M., Krull, C., Hawro, T., Saluja, R., Groffik, A., Stanger, C., Staubach, P., and Maurer, M.: Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. J. Invest. Dermatol. 2014: 134; 2833-2836. IF: 7.22
197. Rogala, B., Bozek, A., Glück, J., Rymarczyk, B., Jarzab, J., and Maurer, M.: Coexistence of angioedema alone with impaired glucose tolerance. Int. Arch. Allergy Immunol. 2014: 165; 265-269. IF: 2.67
196. Saluja, R., Hawro, T., Eberle, J., Church, M. K., and Maurer, M.: Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit independent pathways.Int. J. Immunopathol. Pharmacol. 2014: 28; 575-585. IF: 1.62
195. Hawro, T., Fluhr, J. W., Mengeaud, V., Redoulès, D., Church, M. K., Maurer, M., and Metz, M.: Polidocanol inhibits cowhage- but not histamine-induced itch in humans. Exp. Dermatol. 2014:23; 922-941. IF: 3.76
194. Hiraoka, K., Tashiro, M., Grobosch, T., Maurer, M., Oda, K., Toyohara, J., Ishii, K., Ishiwata, K., and Yanai, K.: Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. Expert Opin. Drug. Saf. 2014: 14; 1-8. IF: 2.91
193. Siebenhaar, F., Metz, M., and Maurer, M.: Mast cells protect from skin tumor development and limit tumor growth during cutaneous de novo carcinogenesis in a Kit-dependent mouse model. Exp. Dermatol. 2014: 23; 159-164. IF: : 3.76
192. Darlenski, R., Kazandjieva, J., Fluhr, J. W., Maurer, M., and Tsankov, N.: Lactic acid sting test does not differentiate between facial and generalized skin functional impairment in sensitive skin in atopic dermatitis and rosacea. J. Dermatol. Sci. 2014: 76; 151-153. IF: 3.42
191. Hawro, T., Maurer M., Hawro, M., Kaszuba, A., Cierpiałkowska, L., Królikowska, M., and Zalewska, A.: In psoriasis, levels of hope and quality of life are linked. Arch. Dermatol. Res. 2014: 306; 661-666. IF: 1.90
191a. Hawro, T., Hawro, M., Zalewska, A., and Maurer, M.: Reply to the letter to the editor on: “In psoriasis, levels of hope and quality of life are linked”. Arch. Dermatol. Res. 2016: 308; 457-458
190. Maurer, M., Longhurst, H. J., Fabien, V., Li, H. H., and Lumry, W. R.: Treatment of hereditary angioedema with icatibant: Efficacy in clinical trials versus effectiveness in the real-world setting. Allergy Asthma Proc. 2014: 35; 377-381. IF: 3.06
189. Prepageran, N., Wang, D. Y., Nair, G., and Maurer, M.: The status quo and unmet needs in the management of allergic rhinitis and chronic rhinosinusitis: a Malaysian perspective. Asia Pac. Allergy 2014: 4; 142-148. IF: N/A
188. Kay, A. B., Ying, S., Ardelean, E., Mlynek, A., Kita, H., Clark, P., and Maurer, M.: Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria. Clin. Exp. Allergy 2014: 44; 1053-1060. IF: 4.77
187. Weller, K., Groffik, A., Church, M. K., Hawro, T., Krause, K., Metz, M., Martus, P., Casale, T., Staubach, P., and Maurer, M.: Development and validation of the urticaria control test - a patient reported outcome instrument for assessing urticaria control. J. Allergy Clin. Immunol. 2014: 133; 1365-1372. IF: 11.47
186. Altrichter, S., Salow, J., Ardelean, E., Church, M. K., Werner, A., and Maurer, M.: Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. J. Dermatol. Sci. 2014: 75; 88-93. IF: 3.42
185. Zuberbier, T., Aberer, W., Asero, R., Bindslev-Jensen, C. Brzoza, Z., Canonica, G. W., Church, M. K., Ensina, L. F., Giménez-Arnau, A., Godse, K., Goncalo, M., Grattan, C., Hebert, J., Hide, M., Kaplan, A., Kapp, A., Abdul Latiff, A. H., Mathelier-Fusade, P., Metz, M., Saini, S. S., Sánchez-Borges, M., Schmid-Grendelmeier P., Simons, F. E., Staubach, P., Sussman, G., Toubi, E., Vena, G. A., Wedi, B., Zhu, X. J., Nast, A., and Maurer, M.: Methods report on the development of the 2013 revision and update of the EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2014:69; e1-e29. IF: 6.03
184. Zuberbier, T., Aberer, W., Asero, R., Bindslev-Jensen, C., Brzoza, Z., Canonica, G. W., Church, M. K., Ensina, L. F., Giménez-Arnau, A., Godse, K., Goncalo, M., Grattan, C., Hebert, J., Hide, M., Kaplan, A., Kapp, A., Abdul Latiff, A. H., Mathelier-Fusade, P., Metz, M., Nast, A., Saini, S. S., Sánches-Borges, M., Schmidt-Grendelmeier, P., Simons, F. E. R., Staubach, P., Sussman, G., Toubi, E., Vena, G. A., Wedi, B., Zhu, X. J., and Maurer, M.: The EAACI/GA²LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of Urticaria. The 2013 revision and update. Allergy 2014:69; 868-887. IF: 6.03
183. Metz, M., Ohanyan, T., Church, M. K., and Maurer, M.: Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Derm. 2014: 150; 288-290. IF: 4.43
182. Magerl, M., Doumoulakis, G., Kalkounou, I., Weller, K., Church, M. K., Kreuz, W., and Maurer, M.: Characterization of prodromal symptoms in a large population of patients with hereditary angioedema. Clin. Exp. Dermatol. 2014: 39; 298-303. IF: 1.09
181. Vieira dos Santos, R., Locks Bidese, B., Rabello de Souza, J., and Maurer, M.: Effects of omalizumab in a patient with three types of chronic urticaria. Brit. J. Dermatol. 2014:170; 469-471. IF: 4.27
180. Metz, M., Ohanyan, T., Church, M. K., and Maurer, M.: Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J. Dermatol. Sci. 2014: 73; 57-62. IF: 3.42
179. Aberer, W., Maurer, M., Reshef, A., Longhurst, H., Kivity, S., Bygum, A., Caballero, T., Bloom, B., Nair, N., and Malbrán, A.: Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy 2014: 69; 305-314. IF: 6.03
178. Vukman, K. V., Adams, P., N., Dowling, D., Metz, M., Maurer, M., and O'Neill, S. M.: The effects of Fasciola hepatica tegumental antigens on mast cell function. Int. J. Parasitol. 2013: 43; 531-539. IF: 3.64
177. Ale, A., Siebenhaar, F., Kosanke, K., Aichler, M., Radrich, K., Heydrich, S., Schiemann, M., Bielicki, I., Noel, P. B., Braren, R., Maurer, M., Walch, A. K., Rummeny, E. J., Nztiachristos, V., and Wildgruber, M.: Cardioprotective C-kit+ bone marrow cells attenuate apoptosis after acute myocardial infarction in mice - in vivo assessment with fluorescence molecular imaging. Theranostics 2013: 3; 903-913. IF: 7.83
176. Weller, K., Koti, I., Makris, M., and Maurer, M.: Anxiety and depression seem less common in patients with autoreactive chronic spontaneous urticaria. Clin. Exp. Dermatol. 2013: 38; 870-873. IF: 1.23
175. Nelissen, S., Vangansewinkel, T., Geurts, N., Geboes, L., Lemmens, E., Vidal, P. M., Lemmens, S., Willems, L., Boato, F., Dooley, D., Pehl, D., Pejler, G., Maurer, M., Metz, M., and Hendrix, S.: Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4. Neurobiol. Dis. 2013: 62C; 260-272. IF: 5.20
174. Magerl, M., Rother, M., Bieber, T., Biedermann, T., Brasch, J., Dominicus, R., Hunzelmann, N., Jakob, T., Mahler, V., Popp, G., Schäkel, K., Schlingensiepen, R., Schmitt, J., Siebenhaar, F., Simon, J. C., Staubach, P., Wedi, B., Weidner, C., and Maurer, M.: Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. J. Eur. Acad. Dermatol. Venereol. 2013: 27; e363-e369. IF: 2.78
173. Bas, M., Greve, J., Hoffmann, T., Reshef, A., Aberer, W., Maurer, M., Kivity, S., Farkas, H., Floccard, B., Arcoleo, F., Martin, L., Sitkauskiene, B., Bouillet, L., Schmid-Grendelmeier, P., Li, H., and Zanichelli, A.: Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy 2013: 68; 1452-1459. IF: 5.99
172. Koti, I., Weller, K., Makris, M., Tiligada, E., Psaltopoulou, T., Papageorgiou, C., Baiardini, I., Panagiotakos, D., Braido, F., and Maurer, M.: Disease activity only moderately correlates with quality of life impairment in patients with chronic spontaneous urticaria. Dermatology 2013: 226; 371-379. IF: 1.68
171. Reiter, N., Reiter, M., Altrichter, S., Becker, S., Kristensen, T., Broesby-Olsen, S., Church, M. K., Metz, M., Maurer, M., and Siebenhaar, F.: Anaphylaxis caused by Mosquito allergy in systemic mastocytosis. Lancet 2013: 382; 1380. IF: 39.21
170. Weller, K., Groffik, A., Magerl, M., Tohme, N., Martus, P., Krause, K., Metz, M., Staubach, P., and Maurer, M.: Development, validation, and initial results of the angioedema activity score. Allergy 2013: 68; 1185-1192. IF: 5.99
169. Krause, K., Mahamed, Aos, Weller, K., Metz, M., Zuberbier, T., and Maurer, M.: Efficacy and safety of canakinumab in urticarial vasculitis: an open label study. J. Allergy Clin. Immunol. 2013:132; 751-754. IF: 11.25
168. Krause, K., Kessler, B., Weller, K., Veidt, J., Chen, S. C., Martus, P., Church, M. K., Metz, M.*, and Maurer, M.*: The German version of ItchyQoL: validation and initial clinical findings. Acta Derm. Venereol. 2013: 93; 562-568. IF: 4.24
167. Zanichelli, A., Magerl, M., Longhurst, H., Fabien, V., and Maurer, M.: Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin. Immunol. 2013: 9; 29. IF: N/A
166. Siebenhaar, F., Förtsch, A., Krause, K., Weller, K., Metz, M., Magerl, M., Martus, P., Church, M. K., and Maurer, M.: Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy 2013:68; 949-952. IF: 5.99
165. Krause, K., Spohr, A., Zuberbier, T., Church. M. K., and Maurer, M.: Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013: 68; 921-928. IF: 5.99
164. Krause, K., Krull, C., Keßler, B., Lange-Asschenfeldt, B., Maurer, M., and Metz, M.: Effective control of recalcitrant pruritus by bevacizumab - a possible role for VEGF in chronic itch? Acta Derm. Venereol. 2013: 2; 175-179. IF: 4.24
163. Kaplan, A., Ledford, D., Ashby, M., Canvin, J, Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., Stirling, R. G., Kuna, P., Berger, W., Maurer, M., and Rosén, K.: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J. Allergy Clin. Immunol. 2013: 132; 101-109. IF: 11.25
162. Maurer, M., Magerl, M., Metz, M., Siebenhaar, F., Weller, K., and Krause, K.: Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy 2013: 68; 816-819. IF: 5.99
161. Metz, M., Krull, C., and Maurer, M.: Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, Neopterin, and VEGF are not elevated in chronic spontaneous urticaria. J. Dermatol. Sci. 2013: 70; 222-225. IF: 3.33
160. Schoepke, N., Church, M. K., and Maurer, M.: The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers. Acta Derm. Venereol. 2013: 93; 286-293. IF: 4.24
159. Nullens, S., Sabato, V., Faber, M., Leysen, J., Bridts, C. H., de Clerck, L. S., Falcone, F., Maurer, M., and Ebo, D. G.: Basophilic histamine content and release during venom immunotherapy: insights by flow cytometry. Cytom. Part B - Clin. CY 2013: 84; 173-178. IF: 2.28
158. Hendrix, S.*, Kramer, P.*, Pehl, D., Warnke, K., Boato, F., Nelissen, S., Lemmens, E., Pejler, G., Metz, M., Siebenhaar, F., and Maurer, M.: Mast cells protect from post-traumatic brain inflammation by the mastcell-specific chymase mouse mast cell protease-4. FASEB J. 2013: 27; 920-929. IF: 5.48
157. Simon, A., Bouchra, A., Braun-Falco, M., De Koning, H., Fermand, J. P., Grattan, C., Krause, K., Lachmann, H., Lenormand, C., Martinez-Taboada, V., Maurer, M., Peters, M., Rizzi, R., Rongioletti, F., Ruzicka, T., Schnitzler, L., Schubert, B., Sibilia, J., and Lipsker, D.: Schnitzler's syndrome: diagnosis, treatment and follow-up. Allergy 2013: 68; 562-568. IF: 5.99
156. Weller, K., Schoepke, N., Krause, K., Ardelean, E., Bräutigam, M., and Maurer, M.: Selected urticaria patients benefit from a referral to tertiary care centers - results of an expert survey. J. Eur. Acad. Dermatol. Venereol. 2013: 27; e8-e16. IF: 2.78
155. Mlynek, A.*, Vieira dos Santos, R.*, Ardelean, E., Weller, K., Magerl, M., Church, M. K., and Maurer, M.: A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clin. Exp. Dermatol. 2013: 38; 360-366. IF: 1.23
154. Vukman, K. V., Adams, P. N., Dowling, D., Metz, M., Maurer, M., and O'Neill, S. M.: Fasciola hepatica tegumental coat impairs mast cells ability to drive Th1 immune responses. J. Immunol. 2013: 190; 2873-2879. IF: 5.36
153. Kalogeromitros, D., Makris, M., Chliva, C., Sergentanis, T. N., Church, M. K., Maurer, M., and Psaltopoulou, T.: An internet survey on self-reported food allergy in Greece: Clinical aspects and lack of appropriate medical consultation. J. Eur. Acad. Dermatol. Venereol. 2013: 27; 558-564. IF: 2.78
152. Maurer, M., Rosén, K., Hsie, H. J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., and Casale, T.: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. New Engl. J. Med. 2013: 368; 924-935. IF: 54.40

Maurer, M., Rosén, K., and Hsie, H. J.: Comment on "Omalizumab for chronic urticaria". New Engl. J. Med. 2013: 368; 2527-2530

Rosén, K., Maurer, M., Hsie, H. J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., and Casale, T.: Comment on "Response to: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal".Brit. J. Dermatol. 2014: 171; 15-16
151. Weller, K.*, Ardelean, E.*, Scholz, E., Martus, P., Zuberbier, T., and Maurer, M.: Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm. Venereol. 2013: 93; 168-174. IF: 4.24
150. Hawro, T., Maurer, M., Sysa-Jędrzejowska, and Woźniacka, A.: Prevalence of nonspecific cutaneous vascular lesions and association with antiphospholipid antibodies in patients with systemic lupus erythematosus. Brit. J. Dermatol. 2013: 168; 213-215. IF: 4.10
149. Krause, K., Giménez-Arnau, A., Martinez-Escala, E., Farré-Albadelejo, M., Abajian, M., Church, M. K., and Maurer, M.: Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. Allergy 2013: 68; 256-258. IF: 5.99
148. Woidacki, K., Popovic, M., Metz, M., Schumacher, A., Linzke, N., Teles, A., Poirier, F., Fest, S., Jensen, F., Rabinovich, G. A.*, Maurer, M. *, and Zenclussen, A. C.*: Mast cells rescue implantation defects caused by c-kit deficiency. Cell Death. Dis. 2013: 4; e462. IF: 5.18
147. Kallinich, T., Gattorno, M., Grattan, C. E., de Koning, H. D., Traidl-Hoffmann, C., Feist, E., Krause, K., Lipsker, D., Navarini, A. A., Maurer, M., Lachmann, H. J., and Simon, A.: Unexplained recurrent fever: when is autoinflammation the explanation? Allergy 2013: 68; 285-296. IF: 5.99
146. Maurer, M., Aberer, W.*, Bouillet, L.*, Caballero, T.*, Fabien, V.*, Kanny, G.*, Kaplan, A.*, Longhurst, H.*, and Zanichelli, A.*: Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS ONE 2013: 8; e53773. IF: 3.53
145. Weller, K., Viehmann, K., Bräutigam, M., Krause, K., Siebenhaar, F., Zuberbier, T., and Maurer, M.: Management of chronic spontaneous urticaria in real life - in accordance with the guidelines? A cross-sectional physician-based survey study. J. Eur. Acad. Dermatol. Venereol. 2013: 27; 43-50. IF: 2.78
144. Konstantinou, G. N., Asero, R., Ferrer, M., Knol, E. F., Maurer, M., Raap, U., Schmid-Grendelmeier, P., Skol, P. S., and Grattan, C. E. H.: EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy 2013: 68; 27-36. IF: 5.99
143. Krause, K., Feist, E., Fiene, M., Kallinich, T., and Maurer, M.: Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J. Allergy Clin. Immunol. 2012: 129; 848-850. IF: 12.04
142. Krause, K., Grattan, C. E., Bindslev-Jensen, C., Gattorno, M., Kallinich, T., de Koning, H. D., Lachmann, H. J., Lipsker, D., Navarini, A. A., Simon, A., Traidl-Hoffmann, C., and Maurer, M.: How not to miss autoinflammatory diseases masquerading as urticaria. Allergy 2012: 67; 1465-1474. IF: 5.88
141. Craig, T., Aygören Pürsün, E., Bork, K., Bowen, T., Boysen, H., Farkas, H., Grumach, A. S., Katelaris, C., Lockey, R., Longhurst, H., Lumry, W. R., Magerl, M., Martinez-Saguer, I., Ritchie, B., Nast, A., Zuraw, B. L., and Maurer, M.: Guideline for the management of hereditary angioedema: World Allergy Organization consensus document. WAO Journal 2012: 5; 182-199. IF: N/A
140. Weller, K., Groffik, A., Magerl, M., Tohme, N., Martus, P., Krause, K., Metz, M., Staubach, P., and Maurer, M.: Development and construct validation of the angioedema Quality of Life Questionnaire (AE-QoL). Allergy 2012: 67; 1289-1298. IF: 5.88
139. Ständer, S., Darsow, U., Mettang, T., Gieler, U., Maurer, M., Ständer, H., Beuers, U., Niemeier, V., Gollnick, H., Vogelgsang, M., and Weisshaar, E.: S2k-Leitlinie - Chronischer Pruritus. J. Dtsch. Dermatol. Ges. 2012: 10; S1-S27. IF: 1.40
138. Zuberbier, T., Aberer, W., Brockow, K., Grabbe, J., Hamelmann, E., Hartmann, K., Jakob, T., Maurer, M., Merk, H. F., Ollert, M., Ruëff, F., Schmid-Grendelmeier, P., Staubach, P., Voigtmann, I., and Wedi, B.: Therapy of urticaria: German language version of the international S3-guideline. Allergologie 2012: 4; 187-208. IF 0.33
137. Hepworth, M. R., Maurer, M., and Hartmann, S.: Regulation of type 2 immunity to helminths by mast cells. Gut Microbes 2012: 3; 1-6. IF 2012: 4.73
136. Kring-Tannert, L., Stahl Skov, P., Bjerremann Jensen, L., Maurer, M., and Bindslev-Jensen, C.: Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatology 2012: 224; 101-105. IF: 2.02
135. Krause, K., Weller, K., Stefaniak, R., Wittkowski, H., Altrichter, S., Siebenhaar, F., Zuberbier, T., and Maurer, M.: Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: An open-label study. Allergy 2012: 67; 943-950. IF: 6.27
134. Kocatürk, E.*, Weller, K.*, Martus, P., Aktas, S., Kavala, M., Sarigul, S., Baiardini, I., Canonica, G. W., Brzoza, Z., Kalogeromitros, and Maurer, M.: Turkish version of the chronic urticaria quality of life questionnaire: cultural adaption, assessment of reliability and validity. Acta Derm. Venereol. 2012: 92; 419-425. IF: 3.48
133. Hepworth, M. R., Danilowicz-Luebert, E., Rausch, S., Metz, M., Klotz, C., Maurer, M., and Hartmann, S.: Mast cells orchestrate type 2 immunity to helminths through regulation of tissue derived cytokines. P. Natl. Acad. Sci. USA 2012: 109; 6644-6649. IF: 9.73
132. Weller, K., Viehmann, K., Bräutigam, M., Krause, K., Siebenhaar, F., Zuberbier, T., and Maurer, M.: Cost-intensive, time-consuming, problematical? - How physicians in private practice experience the care of urticaria patients. J. Dtsch. Dermatol. Ges. 2012: 10; 341-347. IF: 1.40 (EN)
Weller, K., Viehmann, K., Bräutigam, M., Krause, K., Siebenhaar, F., Zuberbier, T., and Maurer, M.: Cost-intensive, time-consuming, problematical? - How physicians in private practice experience the care of urticaria patients. J. Dtsch. Dermatol. Ges. 2012: 10; 341-347. IF: 1.40 (DE)
131. Magerl, M., Pisarevskaja, D., Staubach, P., Martus, P., Church, M. K., and Maurer, M.: Critical temperature threshold measurement for cold urticaria: a randomised controlled trial of H1-antihistamine up-dosing. Brit. J. Dermatol. 2012: 166; 1095-1099. IF: 3.75
130. Bousquet, J., Anto, J. M., Demoly, P., Schünemann, H. J., Togias, A., Akdis, M., Auffray, C., Bachert, C., Bieter, T., Bousquet, P. J., Carlsen, K. H., Casale, T. B., Cruz, A. A., Keil, T., Lodrup-Carlsen, K. C., Maurer, M., Ohta, K., Papadopoulos, N. G., Roman Rodriguez, M., Samolinski, B., Agache, I., Andrianarisoa, A., Annesi-Maesano, I., Ballester, F., Baena-Cagnani, C. E., Basagaña, X., Bateman, E. D., Bel, E. H., Bedbrook, A., Beghue, B., Beji, M., Ben Kheder, A., Benet, M., Benoor, K. S., Bergmann, K. C., Berrissoul, F., Bindslev-Jensen, C., Bleecker, G., Bonini, S., Boner, A. L., Boulet, L. P., Brightling, C. E., Brozek, J. L., Bush, A., Busse, W. W., Camargos, P. A. M., Canonica, G. W., Carr, W., Cesario, A., Chen, Y. Z., Chin-Suorn, A., Chiriac, A., Costa, D. J., Cox, L., Custovic, A., Dahl, R., Darsow, U., Didi, T., Dolen, W. K., Douagui, H., Dubakiene, R., El-Meziane, A., Fonseca, J., Fokkens, W. J., Fthenou, E., Gamkrelidze, A., Garcia-Aymerich, J., Gerth van Wijk, R., Gimeno, E., Guerra, S., Haahtela, T., Haddad, H., Hellings, P., Hellquist-Dahl, B., Hohmann, C., Howarth, P., Hourihane, J. O., Humbert, M., Jacquemin, B., Just, J., Kalayci, O., Kaliner, M. A., Kauffmann, F., Kerkhof, M., Khayat, G., Koffi N'Goran, B., Kogevinas, M., Koppelman, G. H., Kowalski, M. L., Kull, I., Kuna, P., Larenas, D., Lavi, I., Le, L. T., Lieberman, P., Lipworth, B., Mahboub, B., Makela, M. J., Martin, F., Martinez, F. D., Marshall, G. D., Mazon, A., Melen, E., Meltzer, E. O., Mihaltan, F., Mohammad, Y., Mohammadi, A., Momas, I., Morais-Almeida, E. O., Mullol, J., Muraro, A., Naclerio, R., Nafti, S., Namazova-Baranova, L., Nawijn, M. C., Nyembue, D., Oddie, S., O'Hehir, R., Okamoto, Y., Orru, M. P., Ozdemir, C., Ouedraogo, G. S., Palkonen, S., Panzner, P., Passalacqua, G., Pawankar, C., Pigearias, B., Pin, I., Pinart, M., Pison, C., Popov, T. A., Porta, D., Postma, D. S., Price, D., Rabe, K. F., Ratomaharo, J., Reitamo, S., Rezagui, D., Ring, J., Roberts, R., Roca, J., Rogala, B., Romano, A., Rosado-Pinto, J., Ryan, D., Sánchez-Borges, M., Scadding, G. K., Sheikh, A., Simons, F. E. R., Siroux, V., Schmid-Grendelmeier, P., Smit, H. A., Sooronbaev, T., Stein, R. T., Sterk, P. J., Sunyer, J., Terreehorst, I., Toskala, E., Tremblay, Y., Valenta, R., Valeyre, D., Vandenpas, O., van Weel, C., Vassilaki, M., Varraso, R., Viegi, G., Wang, D. Y., Wickman, M., Williams, D., Wöhrl, S., Wright, J., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zernotti, M. E., Zidarn, M., Zhong, N., and Zuberbier, T.: Severe chronic allergic (and related) diseases: a uniform approach - a MeDALL-GA²LEN-ARIA position paper. Int. Arch. Allergy Immunol. 2012: 158; 216-231. IF: 2.24
129. Bork, K., Maurer, M., Bas, M., Hartmann, K., Biedermann, T., Kreuz, W., Aygören-Pürsün, E., Martinez-Saguer, I., Ott, H., and Wedi, B.: Hereditäres Angioödem durch C1-Inhibitor-Mangel. Allergo J. 2012: 2; 109-118. IF: N/A
128. Ngouateu, O. B., Kollo, P., Ravel, C., Derreure, J., Kamtchouing, P., Same-Ekobo, A., von Stebut, E., Maurer, M., and Dondji, B.: Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: Results of a large cross-sectional study. T. Roy. Soc. Trop. Med. H. 2012: 106; 137-142. IF: 1.82
127. Vukman, K. V., Visnovitz, T., Adams, P. N., Metz, M., Maurer, M., and O'Neill, S. M.: Mast cells cultured from IL-3 treated mice show impaired responses to bacterial antigen stimulation. Inflamm. Res. 2012: 61; 79-85. IF: 1.96
126. Maurer, M. and Church, M. K.: Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H1-antihistamines. Exp. Dermatol. 2012: 21; 154-155. IF: 3.57
125. Mathias, S. D., Crosby, R. D., Zazzali, J. L., Maurer, M., and Saini, S. S.: Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann. Allergy Asthma Immunol. 2012: 108; 20-24. IF: 3.44
124. Metz, M., Krause, K., Maurer, M., and Magerl, M.: Treatment of notalgia paresthetica with an 8% capsaicin patch. Br. J. Dermatol. 2011: 165; 1359-1361. IF: 3.66
123. Metz, M., Gilles, S., Geldmacher, A., Behrendt, H., Traidl-Hoffmann, C., and Maurer, M.: Evidence for non-allergic mast cell activation in pollen-associated inflammation. J. Invest. Dermatol. 2011: 131; 987-990. IF: 6.31
122. Kalogeromitros, D., Psaltopoulou, T., Koti, I., Chliva, C., Stefanadi, E., Makris, M., and Maurer, M.: Can internet surveys help us understanding allergic disorders? - Results from a large survey in urticaria in Greece. J. Eur. Acad. Dermatol. Venereol. 2011: 25; 532-537. IF: 2.98
121. Metz, M.*, Schäfer, B.*, Tsai, M., Maurer, M., and Galli, S. J.: Evidence that the endothelin A receptor can enhance IgE-dependent anaphylaxis in mice. J. Allergy Clin. Immunol. 2011: 128; 424-426. IF: 11.00
120. Maurer, M., Bindslev-Jensen, C., Schoepke, N., and Zuberbier, T.: Effects of a novel GA²LEN training program on urticaria on the knowledge of general practitioners in Saudi-Arabia. WAO Journal 2011: 4; 45-46. IF: N/A
119. Weller, K., Church, M. K., Kalogeromitros, D., Krause, K., Magerl, M., Metz, M., Pisarevskaja, D., Siebenhaar, F., and Maurer, M.: Chronic spontaneous urticaria - how to assess quality of life in patients on treatment. Arch. Dermatol. 2011: 147; 1221-1223. IF: 3.88
118. Luckey, U.*, Maurer, M.*, Schmidt, T., Lorenz, N., Seebach, B., Metz, M., and Steinbrink, K.: T cell killing by tolerogenic dendritic cells protects from allergy in mice. J. Clin. Invest. 2011: 121; 3860-3871. IF: 13.06
117. Saini, S., Rosen, K. E., Hsieh, H. J., Wong, D., Conner, E., Kaplan, A., Spector, S., and Maurer, M.: A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J. Allergy Clin. Immunol. 2011: 128; 567-573. IF: 11.00
116. Weller, K., Ziege, C., Staubach, P., Brockow, K., Siebenhaar, F., Krause, K., Altrichter, S., Church, M. K., and Maurer, M.: H1-Antihistamine up-dosing in chronic spontaneous urticaria: Patients' perspective of effectiveness and side effects - a retrospective survey study. PLoS ONE 2011: 6; e23931. IF: 4.09
115. Staubach, P., Dechene, M., Metz, M., Magerl, M., Siebenhaar, F., Weller, K., Zezula, P., Eckhardt-Henn, A., and Maurer, M.: High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm-Venereol. 2011: 91; 557-561. IF: 3.17
114. Maurer, M., Altrichter, S., Bieber, T., Biedermann, T., Bräutigam, M., Seyfried, S, Brehler, R., Grabbe, J., Hunzelmann, N., Jakob, T., Jung, A., Kleine-Tebbe, J., Mempel, M., Meurer, M., Reich, K., Ruëff, F., Sengupta, K., Sieder, C., Simon, J. C., Wedi, B., Zuberbier, T., Mahler, V., and Staubach, P.: Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyreoperoxidase. J. Allergy Clin. Immunol. 2011: 128; 202-209. IF: 11.00

Maurer, M.: Effect of omalizumab on thyroid function and autoantibody levels in patients with chronic spontaneous urticaria. Comment on: Monitoring of thyroid function in patients who exhibit IgE against thyroperoxidase on Omalizumab. J. Allergy Clin. Immunol. 2012: 129; 270
113. Zuberbier, T., Aberer, W., Brockow, K., Grabbe, J., Hamelmann, E., Hartmann, K., Jakob, T., Maurer, M., Merk, H. F., Ollert, M., Ruëff, F., Schmid-Grendelmeier, P., Staubach, P., Voigtmann, I., and Wedi, B.: Therapy of urticaria: German language version of the international S3-guideline. Allergo J. 2011: 20; 259-276. IF: DNA
112. Zuberbier, T., Aberer, W., Brockow, K., Grabbe, J., Hamelmann, E., Hartmann, K., Jakob, T., Merk, H., Ollert, M., Ruëff, F., Schmid-Grendelmeier, P., Staubach, P., Voigtmann, I., Wedi, B., and Maurer, M.: Classification and diagnosis of urticaria: German language version of the international S3-guideline. Allergo J. 2011: 20; 249-258. IF: DNA
111. Baiardini, I.*, Braido, F.*, Bindslev-Jensen, C., Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., Fokkens, W., Gerth van Wijk, R. Giménez-Arnau, A., Godse, K., Grattan, C., Grob, J. J., La Grutta, S., Kalogeromitros, D., Kocatürk, E., Lombardi, C., Pinto, A. M., Ridolo, E., Saini, S. S., Sánchez-Borges, M., Senna, G. E., Terreehorst, I., Todo Bom, A., Toubi, E., Bousquet, J., Zuberbier, T., and Maurer, M.: Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: A GA²LEN taskforce position paper. Allergy 2011: 66; 840-844. IF: 6.27
110. Dudeck, A., Sünder, C., Lopez Kostka, S., von Stebut, E.*, and Maurer, M.*: Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur. J. Immunol. 2011: 41; 1883-1893. IF: 2.52
109. Eller, K., Wolf, D., Huber, J. M., Metz, M., Mayer, G., McKenzie A. N. J., Maurer, M., Rosenkranz, A. R., and Wolf, A. M.: IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune-suppression. J. Immunol. 2011: 186; 83-91. IF: 5.78
108. Franzke, N., Schäfer, I., Jost, K., Blome, C., Rustenbach, S. J., Reich, K., Reusch, M., Maurer, M., and Augustin, M.: A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy 2011: 66; 665-670. IF: 6.27
107. Altrichter, S*., Peter, H.-J.*, Pisarevskaja, D., Metz, M., Martus, P., and Maurer, M.: IgE mediated autoallergy against thyroid peroxidase - a novel pathomechanism of chronic spontaneous urticaria? PLoS ONE 2011: 6; e14794. IF: 4.09
106. Brzoza, Z., Badura-Brzoza, K., Mlynek, A., Magerl, M., Baiardini, I., Canonica, G. W., Weller, K., Kocatürk, E., Kalogeromitros, D., Zalewska-Janowska, A., Zuberbier, T., and Maurer, M.: Adaptation and initial results of the polish version of the GA²LEN chronic urticaria quality of life questionnaire (CU-Q²oL). J. Dermatol. Sci. 2011: 62; 36-41. IF: 3.71
105. Metz, M., Doyle, E., Bindslev-Jensen, C, Watanabe, T., Zuberbier, T., and Maurer, M.: Effects of antihistamines on innate immune responses to severe bacterial infection in mice. Int. Arch. Allergy Immunol. 2011: 155; 355-360. IF: 2.40
104. Metz, M., Altrichter, S., Ardelean, E., Keßler, B., Krause, K., Magerl, M., Siebenhaar, F., Weller, K., Zuberbier, T., and Maurer, M.: Anti-immunglobulin E treatment of patients with recalcitrant physical urticaria. Int. Arch. Allergy Immunol. 2011: 154; 177-180. IF: 2.40
103. Groffik, A., Mitzel-Kaoukhov, H., Magerl, M., Maurer, M., and Staubach, P.: Omalizumab - an effective and safe treatment of therapy resistant chronic spontaneous urticaria. Allergy 2011: 66; 303-305. IF: 6.27
102. Weller, K., Magerl, M., and Maurer, M.: Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J. Eur. Acad. Dermatol. 2011: 25; 119-120. IF: 2.98
101. Krause, K., Ardelean, E., Keßler, B., Magerl, M., Metz, M., Siebenhaar, F., Weller, K., Worm, M., Zuberbier, T., and Maurer, M.: Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy 2011: 65; 1494-1495. IF: 6.27
100. Dölle, S., Hoser, D., Rasche, C., Loddenkemper, C., Maurer, M., Zuberbier, T., and Worm, M.: Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. Allergy 2010: 65; 1158-1165. IF: 6.29
99. Braido, F., Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., Fokkens, W., Gerth van Wijk, R., La Grutta, S., Lombardi, C., Maurer, M., Pinto, A. M., Ridolo, E., Senna, G. E., Terreehorst, I., Todo Bom, A., Bousquet, J., Zuberbier, T., and Baiardini, I.: Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA2LEN taskforce position paper. Allergy 2010: 65; 959-968. IF: 6.29
98. Magerl, M., Staubach, P., Altrichter, S., Ardelean, E., Krause, K., Metz, M., Weller, K., and Maurer, M.: Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J. Allergy Clin. Immun. 2010: 126; 665-666. IF: 9.27
97. Cicardi, M.*, Banerji, A.*, Bracho, F., Malbrán, A., Rosenkranz, B., Riedl, M., Bork, K., Lumry, W., Aberer, W., Bier, H., Bas, M., Greve, J., Hoffmann, T. K., Farkas, H., Reshef, A., Ritchie, B., Yang, W., Grabbe, J., Kivity, S., Kreuz, W., Levy, R. J., Luger, T., Obtulowicz, K., Schmidt-Grendelmeier, P., Bull, C., Sitkauskiene, B., Smith, W. B., Toubi, E., Werner, S., Anné, S., Björkander, J., Bouillet, L., Cillari, E., Hurewitz, D., Jacobson, K. W., Katelaris, C. H., Maurer, M., Merk, H., Bernstein, J. A., Feighery, C., Floccard, B., Gleich, G., Hébert, J., Kaatz, M., Keith, P., Kirkpatrick, C. H., Langton, D., Martin, L., Pichler, C., Resnick, D., Wombolt, D., Fernández Romero, D. S., Zanichelli, A., Arcoleo, F., Knolle, J., Kravec, I., Dong, L., Zimmermann, J., Rosen, K., and Fan, W.-T.: Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. New Engl. J. Med. 2010: 363; 532-541. IF: 53.48
96. Zuberbier, T., Balke, M., Worm, M., Edenharter, G., and Maurer, M.: Epidemiology of urticaria: a representative cross-sectional population survey. Clin. Exp. Dermatol. 2010: 35; 869-873. IF: 1.26
95. Hartmann, K.*, Siebenhaar, F.*, Belloni, B., Brockow, K., Eben, R., Hartmann, B., Ruëff, F., Schoepke, N., Staubach, P., Weber, A., and Maurer, M.: Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized double-blind, placebo-controlled trial. Brit. J. Dermatol. 2010: 162; 185-190. IF: 4.35
94. Vieira dos Santos, R., Magerl, M., Martus, P., Zuberbier, T., Church, M. K., Escribano, L., and Maurer, M.: Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Brit. J. Dermatol. 2010: 162; 674-676. IF: 4.35
93. Krause, K., Metz, M., Zuberbier, T., Maurer, M., and Magerl, M.: Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant. J. Dtsch. Dermatol. Ges. 2010: 8; 272-274. IF: 1.48
92. Dudeck, A., Grusser, M., Dudeck, J., and Maurer, M.: Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E- and P-selectin, VCAM-1 and PECAM-1. Exp. Dermatol. 2010: 19; 424-434. IF: 4.15
91. Mlynek, A., Magerl, M., Siebenhaar, F., Weller, K., Vieira dos Santos, R., Zuberbier, T., Zalewska-Janowska, A., andMaurer, M.: Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Brit. J. Dermatol. 2010: 162; 198-200. IF: 4.35
90. Baiardini, I., Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., Fokkens, W., van Wijk, G. R., La Grutta, S., Lombardi, C.,Maurer, M., Pinto, A. M., Ridolo, E., Senna, G. E., Terreehorst, I., Bom, A. T., Bousquet, J., Zuberbier, T., and Braido, F.: Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: A GA2LEN taskforce position paper. Allergy 2010: 65; 290-295. IF: 6.29
89. Metz, M., Scholz, E., Ferrán, M., Izquierdo, I., Giménez-Arnau, A., andMaurer, M.: Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann. Allergy Asthma Immunol. 2010: 104; 86-92. IF: 2.80
88. Bachert, C. andMaurer, M.: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria. Results of four postmarketing surveillance studies. Clin. Drug Invest. 2010: 30; 109-122. IF: 1.62
87. Magerl, M., Pisarevskaja, D., Scheufele, R., Zuberbier, T., andMaurer, M.: Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: A prospective trial. Allergy 2010: 65; 78-83. IF: 6.29
86. Hartmann, K., Biedermann, T., Brockow, K., Grabbe, J., Horny, H.-P., Lippert, U.,Maurer, M., Raithel, M., Rietschel, E., Ruëff, F., and Sotlar, K. für das Kompetenznetzwerk Mastozytose e. V.: Leitlinie Mastozytose. Allergol. 2009: 32; 199-213. IF: 2009: 0.12
85. Magerl, M., Borzova, E., Giménez-Arnau, A., Grattan, C. E. H., Lawlor, F., Mathelier-Fusade, P., Metz, M., Mlynek, A., andMaurer, M.: The definition and diagnostic testing of physical and cholinergic urticarias - EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy 2009: 64; 1715-1721. IF: 6.38
84. Konstantinou, G. N., Asero, R.,Maurer, M., Sabroe, R. A., Schmid-Grendelmeier, P., and Grattan, C. E. H.: EAACI/GA2LEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009: 64; 1256-1268. IF: 6.38
83. Schulz, S., Metz, M., Siepmann, D., Luger, T. A.,Maurer, M., and Ständer, S.: Antipruritic efficacy of a high-dosage antihistamine therapy: Results of a retrospectively analysed case series. Hautarzt 2009: 60; 564-568. IF: 0.43
82. Weller, K., Artuc, M., Jennings, G., Friedrichson, T., Guhl, S., Vieira dos Santos, R., Sünder, C., Zuberbier, T., andMaurer, M.: Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. J. Invest. Dermatol. 2009: 129; 496-498. IF: 5.54
81. Weller, K. andMaurer, M.: Desloratadine inhibits human skin mast cell activation and histamine release. J. Invest. Dermatol. 2009: 129; 2723-2726. IF: 5.54
80. Zuberbier, T., Asero, R., Bindslev-Jensen, C., Canonica, G. W., Church, M. K., Giménez-Arnau, A. M., Grattan, C. E. H., Kapp, A., Merk, H. F., Rogala, B., Saini, S., Sánchez-Borges, M., Schmid-Grendelmeier, P., Schünemann, H., Staubach, P., Vena, G. A., Wedi, B., andMaurer, M.: EAACI/GA2LEN/EDF/WAO Guideline: Definition, classification and diagnosis of urticaria. Allergy 2009: 64; 1417-1426. IF: 6.38
79. Zuberbier, T., Asero, R., Bindslev-Jensen, C., Canonica, G. W., Church, M. K., Giménez-Arnau, A. M., Grattan, C. E. H., Kapp, A.,Maurer, M., Merk, H. F., Rogala, B., Saini, S., Sánchez-Borges, M., Schmid-Grendelmeier, P., Schünemann, H., Staubach, P., Vena, G. A., and Wedi, B.: EAACI/GA2LEN/EDF/WAO Guideline: Management of urticaria. Allergy 2009: 64; 1427-1443. IF: 6.38
78. Giménez-Arnau, A., Izquierdo, I., andMaurer, M.: The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J. Eur. Acad. Dermatol. Venereol. 2009: 23; 1088-1091. IF: 2.79
77. Maurer, M., Ortonne, J.-P., and Zuberbier, T.: Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation. Allergy 2009: 64; 581-588. IF: 6.38
76. Mlynek, A.*, Magerl, M.*, Hanna, M., Lhachimi, S., Baiardini, I., Canonica, G. W., Brzoza, Z., Kasperska-Zajac, A., Rogala, B., Zalewska-Janowska, A., Zuberbier, T., andMaurer, M.: The German version of the chronic urticaria quality-of-life questionnaire (CU-Q2oL): Factor analysis, validation and initial clinical findings. Allergy 2009: 64; 927-936. IF: 6.38
75. Metz, M.*, Magerl, M.*, Kühl, N. F., Valeva, A., Bhakdi, S., andMaurer, M.: Mast cells determine the magnitude of bacterial toxin-induced skin inflammation. Exp. Dermatol. 2009: 18; 160-166. IF: 3.24
74. Mrabet-Dahbi, S.*, Metz, M.*, Dudeck, A., Zuberbier, T., andMaurer, M.: Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Exp. Dermatol. 2009: 18; 437-444. IF: 3.24
73. Potter, P. C., Kapp, A.,Maurer, M., Guillet, G., Jian, A. M., Hauptmann, P., and Finlay, A. Y.: Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy 2009: 64; 596-604. IF: 6.38
72. Metz, M., Gimenez-Arnau, A., Borzova, E., Grattan, C. E. H., Magerl, M., andMaurer, M.: Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. J. Allergy Clin. Immunol. 2009: 123; 705-706. IF: 9.16
Metz, M., Gimenez-Arnau, A., Borzova, E., Grattan, C. E. H., Magerl, M., andMaurer, M.: Comment on "Is the autologous plasma skin test in patients with chronic urticaria really useless?" J. Allergy Clin. Immunol. 2009: 123; 1417.
71. Altrichter, S., Boodstein, N., andMaurer, M.: Matrix metalloproteinase-9: A novel biomarker for monitoring disease activity in patients with chronic urticaria? Allergy 2009: 64; 652-656. IF: 6.38
70. Siebenhaar, F., Degener, F., Zuberbier, T., Martus, P., andMaurer, M.: High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J. Allergy Clin. Immunol. 2009: 123; 672-679. IF: 9.16
69. Magerl, M., Schmolke, J., Metz, M., Zuberbier, T., Siebenhaar, F., andMaurer, M.: Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clin. Exp. Dermatol. 2009: 34; e137-e140. IF: 1.55
68. Maurer, M., Ortonne, J.-P., and Zuberbier, T.: Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Brit. J. Dermatol. 2009: 160; 633-641. IF: 4.26
67. Vieira dos Santos, R., Metz, M., Lima, H. C., Martus, P., andMaurer, M.: Differential effects of skin nerves on allergic skin inflammation. Allergy 2009: 64; 496-498. IF: 6.38
66. Staubach, P., Vonend, A., Burow, G., Metz, M., Magerl, M., andMaurer, M.: Patients with chronic urticaria exhibit increased rates of sensitisation to Candida albicans, but not to common moulds. Mycoses 2008: 52; 334-338. IF: 1.53
65. Zuberbier, T.,Maurer, M., and Augustin, M.: Use of topical steroids is largely restricted by irrational emotional concerns in both patients and physicians. Allergy 2008: 63; 1560-1561. IF: 6.20
64. Güzelbey, O., Ardelean, E., Magerl, M., Zuberbier, T.,Maurer, M., and Metz, M.: Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008: 63; 1563-1565. IF: 6.20
63. Vieira dos Santos, R., Mlynek, A., Lima, H. C., Martus, P., andMaurer, M.: Beyond flat weals: validation of a three-dimensional imaging technology that will improve skin allergy research. Clin. Exp. Dermatol. 2008: 33; 772-775. IF: 1.78
62. Caucig, P., Lescau, S., Knop, J.,Maurer, M., and von Stebut, E.: Interleukin-2 immediate type hypersensitivity? J. Dtsch. Dermatol. Ges. 2008: 6; 956-956. IF: N/A
61. Siebenhaar, F., Magerl, M., Peters, E. M. J., Hendrix, S., Metz, M., andMaurer, M.: Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. J. Allergy Clin. Immunol. 2008: 121; 955-961. IF: 9.77
60. Mlynek, A., Zalewska-Janowska, A., Martus, P., Staubach, P., Zuberbier, T., andMaurer, M.: How to assess disease activity in patients with chronic urticaria? Allergy 2008: 63; 777-780. IF: 6.20
59. Magerl, M.*, Lammel, V.*, Siebenhaar, F., Zuberbier, T., Metz, M., andMaurer, M.: Non-pathogenic commensal Escherichia coli bacteria can inhibit degranulation of mast cells. Exp. Dermatol. 2008: 17; 427-435. IF: 3.26
58. Metz, M., Bergmann, P., Zuberbier, T., andMaurer, M.: Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008: 63; 247-249. IF: 6.20
57. Magerl, M., Schmolke, J, Siebenhaar, F., Zuberbier, T., Metz, M., andMaurer, M.: Acquired cold urticaria symptoms can be safely prevented by Ebastine. Allergy 2007: 62; 1465-1468. IF: 5.01
56. Orinska, Z.*,Maurer, M.*, Mirghomizadeh, F.*, Bulanova, E., Metz, M., Nashkevich, N., Schiemann, F., Schulmistrat, J., Budagian, V., Giron-Michel, J., Brandt, E., Paus, R., and Bulfone-Paus, S.: IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nature Medicine 2007: 13; 927-934. IF: 26.38
55. Maurer, M.and Zuberbier, T.: Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 2007: 62; 1057-1063. IF: 5.01
54. Staubach-Renz, P., von Stebut, E., Bräuninger, W.,Maurer, M., and Steinbrink, K.: Hypocomplementemic urticarial vasculitis syndrome. Successful therapy with intravenous immunoglobulins. Hautarzt 2007: 58; 693-697. IF: 0.33
53. Siebenhaar, F., Kühn, W., Zuberbier, T., andMaurer, M.: Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. J. Allergy Clin. Immunol. 2007: 120; 213-215. IF: 8.12
52. Siebenhaar, F., Syska, W., Weller, K., Magerl, M., Zuberbier T., Metz, M., andMaurer, M.: Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent. Am. J. Pathol. 2007: 170; 1910-1916. IF: 5.49
51. Magerl, M., Philipp, S., Manasterski, M., Friedrich, M., andMaurer, M.: Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J. Allergy Clin. Immunol. 2007: 119; 752-754. IF: 8.12
50. Siebenhaar, F., Sharov, A. A., Peters, E. M. J., Sharova, T. Y., Syska, W., Mardaryev, A. N., Freyschmidt-Paul, P., Sundberg, J. P.,Maurer, M., and Botchkarev, V. A.: Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (Alopecia Areata). J. Invest. Dermatol. 2007: 127; 1489-1497. IF: 4.83
49. Metz, M., Lammel, V., Gibbs, B.F., andMaurer, M.: Inflammatory murine skin responses to UV-B light are partially dependent on Endothelin-1 and mast cells. Am. J. Pathol. 2006: 169; 815-822. IF: 5.92
48. Zuberbier, T., Bindslev-Jensen, C., Canonica, W., Grattan, C. E. H., Greaves, M. W., Henz, B. M., Kapp, A., Kozel, M. M. A.,Maurer, M., Merk, H. F., Schäfer, T., Simon, D., Vena, G. A., and Wedi, B.: EAACI/GA²LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006: 61; 316-320. IF: 5.33
47. Zuberbier, T., Bindslev-Jensen, C., Canonica, W., Grattan, C. E. H., Greaves, M. W., Henz, B. M., Kapp, A., Kozel, M. M. A.,Maurer, M., Merk, H. F., Schäfer, T., Simon, D., Vena, G. A., and Wedi, B.: EAACI/GA²LEN/EDF guideline: management of urticaria. Allergy 2006: 61; 321-331. IF: 5.33
46. Maurer, M., Lopez Kostka, S., Siebenhaar, F., Moelle, K., Metz, M., Knop, J., and von Stebut, E.: Skin mast cells control T cell-dependent host defence in Leishmania major infections. FASEB J. 2006: 20; 2460-2467. IF: 6.72
45. Weller, K., Foitzik, F., Paus, R., Syska, W., andMaurer, M.: Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006: 20; 2366-2368. IF: 6.72
44. Staubach, P., Onnen, K., Vonend, A., Metz, M., Siebenhaar, F., Tschentscher, I., Opper, B., Magerl, M., Lüdtke, R., Kromminga, A., andMaurer, M.: Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: A placebo-controlled trial. Dermatology 2006: 212; 150-159. IF: 1.85
43. Staubach, P., Eckhardt-Henn, A., Dechene, M., Hanau, A., Metz, M., Magerl, M., Breuer, P., andMaurer, M.: Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Brit. J. Dermatol. 2006: 154; 294-298. IF: 3.33
42. Hendrix, S.*, Warnke, K.*, Siebenhaar, F., Peters, E. M. J., Nitsch, R., andMaurer, M.: The majority of brain mast cells in B10.PL mice is present in the hippocampal formation. Neurosci. Lett. 2006: 392; 174-177. IF: 2.09
41. Weber, A., andMaurer, M.: Skin site mast cell numbers correlate with rates of nodular growth, but not incidence, of basal cell carcinoma. Dermatology 2005: 211; 298-299. IF: 1.83
40. Hochegger, K., Siebenhaar, F., Vielhauer, V., Heininger, D., Mayadas, T. N., Mayer, G.,Maurer, M., and Rosenkranz, A. R.: Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. Eur. J. Immunol. 2005: 35; 3074-3082. IF: 4.87
Hochegger, K., Rosenkranz, A.R., Siebenhaar, F., andMaurer, M.: Comment on "Mast cell-mediated remodelling and fibrinolytic activity protect against fatal glomerulonephritis". J. Immunol. 2006: 177; 1377.
39. Orinska, Z., Bulanova, E., Budagian, V., Metz, M.,Maurer, M., and Bulfone-Paus, S.: TLR3-induced activation of mast cells modulates CD8+ T cell-recruitment. Blood 2005: 106; 978-987. IF: 10.13
38. Maurer, M.and Galli, S. J.: Lack of significant skin inflammation during elimination by apoptosis of large numbers of mouse cutaneous mast cells after cessation of treatment with SCF. Lab. Invest. 2004: 84; 1593-1602. IF: 3.7
37. Maurer, M.*, Wedemeyer, J.*, Metz, M., Chatterjea, D., Clouthier, D. E., Yanagisawa, M., Tsai, M., and Galli, S. J.: Mast cells promote homeostasis by limiting endothelin-1 induced toxicity. Nature 2004: 432; 512-516. IF: 32.18
36. Siebenhaar, F., Staubach, P., Metz, M., Magerl, M., Jung, J., andMaurer, M.: Peltier effect-based temperature challenge - an improved method for diagnosing cold urticaria. J. Allergy Clin. Immunol. 2004: 114; 1224-1225. IF: 7.2
35. Giménez-Arnau, A. M., Ferrer-Puga, M., Peter, H.-J.,Maurer, M., and Pujol-Vallverdú, R. M.: Chronic urticaria: Prospective ethiologic study and autoimmune syndrome significance. Acta Dermo-Sifiliográfica 2004: 95; 560-566. IF: DNA
34. Metz, M., Botchkarev, V. A., Botchkareva, N. V., Welker, P., Tobin, D., Knop, J.,Maurer, M., and Paus, R.: Neurotrophin-3 regulates mast cell functions in neonatal mouse skin. Exp. Dermatol. 2004: 13; 273-281. IF: 1.7
33. Peters, E. M.,Maurer, M., Botchkarev, V. A., deMasey Jensen, K., Welker, P., Scott, G. A., and Paus, R.: Kit is expressed by epithelial cells in vivo. J. Invest. Dermatol. 2003: 121; 976-984. IF: 4.19
32. Maurer, M.*, Seidel-Guyenot, W.*, Metz, M., Knop, J., and Steinbrink, K.: Critical role of IL-10 in the induction of low zone tolerance to contact allergens. J. Clin. Invest. 2003: 112; 432-439. IF: 14.3
31. Weber, A., Knop, J., andMaurer, M.: Pattern analysis of human cutaneous mast cell populations by total body surface mapping. Br. J. Dermatol. 2003: 148; 224-228. IF: 2.69
30. Stebut, E. von, Metz, M., Milon, G., Knop, J., andMaurer, M.: Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1 /β released from neutrophils recruited by mast cell-derived TNF. Blood 2003: 101; 210-215. IF: 10.12
29. Peters, E. M., Tobin, D. J., Botchkareva, N.,Maurer, M., and Paus, R.: Migration of melanoblasts into the developing murine hair follicle is accompanied by transient c-Kit expression. J. Histochem. Cytochem. 2002: 50; 751-766. IF: 1.15
28. Botchkarev, V. A., Komarova, E. A, Siebenhaar, F., Botchkareva, N. V., Sharov, A. A., Komarov, P. G.,Maurer, M., Gudkov, A. V., and Gilchrest, B. A.: p53 involvement in the control of murine hair follicle regression. Am. J. Pathol. 2001: 158; 1913-1919. IF: 7.1
27. Botchkarev, V. A., Komarova, E. A., Siebenhaar, F., Botchkareva, N. V., Komarov, P. G.,Maurer, M., Gilchrest, B. A., and Gudkov, A. V.: p53 is essential for chemotherapy-induced hair loss. Cancer Res. 2000: 60; 5002-5006. IF: 8.46
26. Gommerman, J. L.*, Oh, D. Y.*, Zhou, X., Tedder, T. F.,Maurer, M., Galli, S. J., and Carroll, M. C.: A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J. Immunol. 2000: 165; 6915-6921. IF: 6.83
25. Cindik, E. D.,Maurer, M., Hannan, M. K., Müller, R., Hayes, W. C., Hovy, L., and Kurth, A.: Phenotypical characterization of c-kit receptor deficient mouse femurs using non-destructive high-resolution imaging techniques and biomechanical testing. Technol. Health Care 2000: 8; 267-275. IF: DNA
24. Foitzik, K., Lindner, G., Mueller-Roever, S.,Maurer, M., Botchkareva, N., Botchkarev, V., Handjiski, B., Metz, M., Hibino, T., Soma, T., Dotto, G. P., and Paus, R.: Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J. 2000: 14; 752-760. IF: 9.25
23. Maurer, M., Tsai, M., Metz, M., Fish, S., Korsmeyer, S. J., and Galli, S. J.: A role for Bax in the regulation of apoptosis in mouse mast cells. J. Invest. Dermatol. 2000: 114; 1205-1206. IF: 4.54
22. Paus, R., Müller-Röver, S., Van Der Veen, C.,Maurer, M., Eichmüller, S., Ling, G., Hofmann, U., Foitzik, K., Mecklenburg, L., and Handjiski, B.: A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J. Invest. Dermatol. 1999: 113; 523-532. IF: 4.9
21. Peters, E. M.,Maurer, M., Botchkarev, V. A., Gordon, D. S., and Paus, R.: Hair growth-modulation by adrenergic drugs. Exp. Dermatol. 1999: 8; 274-281. IF: 2.1
20. Botchkarev, V. A., Peters, E. M., Botchkareva, N. V.,Maurer, M., and Paus, R.: Hair cycle-dependent changes in adrenergic skin innervation and hair growth modulation by adrenergic drugs. J. Invest. Dermatol. 1999: 113; 878-887. IF: 4.9
19. Rosenkranz, A. R., Coxon, A.*,Maurer, M.*, Gurish, M. F., Austen, K. F., Friend, D. S., Galli, S. J., and Mayadas, T. N.: Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J. Immunol. 1998: 161; 6463-6467. IF: 7.16
18. Maurer, M., Echtenacher, B.*, Hültner, L.*, Kollias, G., Männel, D. N., Langley, K. E., and Galli, S. J.: The c-kit ligand, stem cell factor, can enhance immunity through effects on mast cells. J. Exp. Med. 1998: 188; 1-6. IF: 15.88
17. Boesiger, J., Tsai, M.,Maurer, M., Yamaguchi, M., Brown, L. F., Claffey, K. P., Dvorak, H. F., and Galli, S. J.: Mast cells can secret VPF/VEGF and exhibit enhanced release after IgE-dependent upregulation of FceRI expression. J. Exp. Med. 1998: 188; 1135-1145. IF: 15.88
16. Maurer, M., Peters, E. M. J., Botchkarev, V. A., and Paus, R.: Intact hair follicle innervation is not essential for anagen induction and development. Arch. Dermatol. Res. 1998: 290; 574-578. IF: 1.42
15. Biró, T.,Maurer, M., Modarres, S., Lewin, N. E., Brodie, C., Acs, G., Acs, P., Paus, R., and Blumberg, P.: Characterization of functional vanilloid receptors - expressed by mast cells. Blood 1998: 91; 1332-1340. IF: 8.3
14. Stebut, E. von,Maurer, M., and Zuberbier, T.: Intoleranzreaktion auf systemische Kortikosteroide. Allergologie 1997: 7; 336-339. IF: 0.56
13. Prodeus, A., Zhou, X.,Maurer, M., Galli, S. J., and Carroll, M. C.: Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 1997: 390; 172-175. IF: 27.36
12. Maurer, M., Fischer, E., Handjiski, B., Stebut, E. von, Algermissen, B., Bavandi, A., and Paus, R.: Activated skin mast cells are involved in murine hair follicle regression (catagen). Lab. Invest. 1997: 77; 319-332. IF: 4.65
11. Botchkarev, V. A., Eichmüller, S., Peters, E., Pietsch, P., Johansson, O.,Maurer, M., and Paus, R.: A simple immunofluorescent technique for simultaneous visualisation of mast cells and nerve fibers reveals selectivity and hair cycle-dependent changes in mast cell-nerve fibre contacts in murine skin. Arch. Dermatol. Res. 1997: 289; 292-302. IF: 1.23
10. Maurer, M., Opitz, M., Henz, B. M., and Paus, R.: The mast cell products histamine and serotonin stimulate and TNF-alpha inhibits the proliferation of murine epidermal keratinocytes in situ. J. Dermatol. Sci. 1997: 16; 79-84. IF: 0.57
9. Slominski, A., Goodman-Snitkoff, G.,Maurer, M., and Paus, R.: Hair cycle-associated changes in splenocyte proliferation. In Vivo 1997: 11; 101-102. IF: 0.44
8. Maurer, M., Handjiski, B., and Paus, R.: Hair growth modulation by topical immunophilin ligands: Induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Am. J. Pathol. 1997: 150; 1433-1441. IF: 6.5
7. Slominski, A., Paus, R., Plonka, P., Handjiski, B.,Maurer, M., Chakraborty, A., and Mihm, M.: Pharmacological disruption of hair follicle pigmentation by cyclophosphamid as a model for studying the melanocyte response to and recovery from cytotoxic drug damage in situ. J. Invest. Dermatol. 1996: 106; 1203-1211. IF: 4.7
6. Paus, R., Böttge, J. A., Czarnetzki, B. M., andMaurer, M.: Hair growth control by immunosuppression. Arch. Dermatol. Res. 1996: 288; 408-410. IF: 1.47
5. Maurer, M., Paus, R., and Czarnetzki, B. M.: Mast cells as modulators of hair follicle cycling. Exp. Dermatol. 1995: 4; 266-271. IF: DNA
4. Paus, R., Heinzelmann, T., Robiscek, S., Czarnetzki, B. M., andMaurer, M.: Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch. Dermatol. Res. 1995: 287; 500-502. IF: 1.33
3. Slominski, A., Chassalevris, N., Mazurkiewicz, J.,Maurer, M., and Paus, R.: Murine skin as a target for melatonin bioregulation. Exp. Dermatol. 1994: 3; 45-50. IF: DNA
2. Slominski, A., Paus, R., Plonka, P., Chakraborty, A.,Maurer, M., Pruski, D., and Lukiewicz, S.: Melanogenesis during the anagen-, catagen-, telogen transformation of the murine hair follicle. J. Invest. Dermatol. 1994: 102; 862-869. IF: 3.6
1. Paus, R.,Maurer, M., Slominski, A., and Czarnetzki, B. M.: Mast cell involvement in murine hair growth. Dev. Biol. 1994: 163; 230-240. IF: 4.7

Anzahl der Originalarbeiten: 323
Gesamt-Impact-Factor der Originalarbeiten: 1836.70

Nach oben